What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2023-07-28 compared with 2023-05-10 · 1341 added, 1292 removed, 278 unchanged (90% of the section changed)

Risks Associated with Our Company

business is subject to numerous risks and uncertainties, including those in the section entitled “ Risk

Factors ” and elsewhere in this Report.

business is subject to numerous risks and uncertainties, including those in the section entitled “Risk Factors” and elsewhere

in this Report.

These risks include, but are not limited to, the following:

We have a limited

operating history, have produced only a limited amount of products and have generated only limited revenues to date;

Our ability to execute

our growth strategy and scale our operations and risks associated with such growth, and our ability to attract members and customers;

The effect of the COVID-19

pandemic, and governmental responses thereto on our operations, those of our vendors, our customers and the economy in general;

Risks associated with our

ED product which has not been, and will not be, approved by the FDA and has not had the benefit of the U.S.

Food and Drug Administration’s

(“ FDA’s ”) clinical trial protocol which seeks to prevent the possibility of serious patient injury and death;

Risks that the FDA may

determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic

Act (“ FFDCA Act ”) provided by Section 503A;

Risks associated with related

party relationships and agreements;

The effect of data security

breaches, malicious code and/or hackers;

Competition and our ability

to create a well-known brand name;

Changes in consumer tastes

and preferences;

Material changes and/or

terminations of our relationships with key parties;

have a limited operating history, have produced only a limited amount of products and have generated only limited revenues to date;

ability to execute our growth strategy and scale our operations and risks associated with such growth, and our ability to attract

members and customers;

effect of pandemics and governmental responses thereto on our operations, those of our vendors, our customers and the

economy in general;

associated with our ED product which has not been, and will not be, approved by the FDA and has not had the benefit of the U.S.

and Drug Administration’s (“ FDA’s ”) clinical trial protocol which seeks to prevent the possibility

of serious patient injury and death;

that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food,

Drug, and Cosmetic Act (“ FFDCA Act ”) provided by Section 503A;

Our significant reliance on related party transactions and risks associated

with such related party relationships and agreements;

effect of data security breaches, malicious code and/or hackers;

and our ability to create a well-known brand name;

in consumer tastes and preferences;

changes and/or terminations of our relationships with key parties;

product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause

health issues;

Our ability to innovate,

expand our offerings and compete against competitors which may have greater resources;

Our significant reliance

on related party transactions;

Our Chairman and Chief

Executive Officer, Jacob D.

Cohen, has majority voting control over the company which may deter some investors;

Our ability to prevent

credit card and payment fraud;

Risks associated with inflation,

and increases in interest rates and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health

and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict) and other large-scale crises;

The risk of unauthorized

access to confidential information;

Our ability to protect

our intellectual property and trade secrets, claims from third-parties that we have violated their intellectual property or trade

secrets and potential lawsuits in connection therewith;

Our and our providers’

ability to comply with government regulations, changing regulations and laws, penalties associated with any non-compliance (inadvertent

or otherwise), the effect of new laws or regulations, and our ability to comply with such new laws or regulations;

Our reliance on our current

management and the terms of their employment agreements with us;

The outcome of future lawsuits,

litigation, regulatory matters or claims;

The fact that certain recent

initial public offerings of companies with public floats comparable to the public float of the Company have experienced extreme volatility

that was seemingly unrelated to the underlying performance of the respective company;

and the fact that we may experience similar

volatility, which may make it difficult for investors to assess the value of our common stock;

Certain terms and provisions

of our governing documents which may prevent a change of control, and which provide for indemnification of officers and directors,

limit the liability of officers or directors, and provide for the board of director’s ability to issue blank check preferred

The anticipated volatile

nature of the trading price of our common stock following the IPO;

and dilution which may be caused by future sales of securities.

have been no material changes to the risk factors set forth in the section titled “ Risk Factors ” included in

our Prospectus, dated March 20, 2023, filed with the Securities and Exchange Commission (“SEC”) in accordance with Rule 424(b)

of the Securities Act on March 22, 2023 (the “Prospectus”) in connection with our initial public offering (“IPO”).

ability to innovate, expand our offerings and compete against competitors which may have greater resources;

Our Chairman and Chief Executive Officer, Jacob D.

Cohen and our President,

Chief Operating Officer and Director, Jonathan Arango, have majority voting control over the company which may deter some investors;

ability to prevent credit card and payment fraud;

associated with inflation, and increases in interest rates and economic downturns, including potential recessions, as well as macroeconomic,

geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict) and other large-scale

risk of unauthorized access to confidential information;

ability to protect our intellectual property and trade secrets, claims from third-parties that we have violated their intellectual

property or trade secrets and potential lawsuits in connection therewith;

and our providers’ ability to comply with government regulations, changing regulations and laws, penalties associated with

any non-compliance (inadvertent or otherwise), the effect of new laws or regulations, and our ability to comply with such new laws

or regulations;

reliance on our current management and the terms of their employment agreements with us;

outcome of future lawsuits, litigation, regulatory matters or claims;

fact that certain recent initial public offerings of companies with public floats comparable to the public float of the Company have

experienced extreme volatility that was seemingly unrelated to the underlying performance of the respective company;

that we may experience similar volatility, which may make it difficult for investors to assess the value of our common stock;

terms and provisions of our governing documents which may prevent a change of control, and which provide for indemnification of officers

and directors, limit the liability of officers or directors, and provide for the board of director’s ability to issue blank

check preferred stock;

anticipated volatile nature of the trading price of our common stock following the IPO;

and dilution which may be caused by future

sales of securities.

business involves significant risks.

1 unchanged sentence

the other information in this Quarterly Report on Form 10-Q and in our other public filings, as well as our audited financial statements

and related notes as disclosed in the Prospectus in connection with our IPO.

The risks and uncertainties described below are not the

only ones we face.

Additional risk and uncertainties that we are unaware of or that we deem immaterial may also become important factors

that adversely affect our business.

The realization of any of these risks and uncertainties could have a material adverse effect on our

reputation, business, financial condition, results of operations, growth and future prospects as well as our ability to accomplish our

strategic objectives.

In that event, the market price of our common stock could decline and you could lose part or all of your investment.

and related notes as disclosed in the Prospectus, dated March 20, 2023, filed with the Securities and Exchange Commission (“SEC”)

in accordance with Rule 424(b) of the Securities Act on March 22, 2023 (the “Prospectus”) in connection with our initial

public offering (“IPO”).

The risks and uncertainties described below are not the only ones we face.

Additional risk and uncertainties

that we are unaware of or that we deem immaterial may also become important factors that adversely affect our business.

The realization

of any of these risks and uncertainties could have a material adverse effect on our reputation, business, financial condition, results

of operations, growth and future prospects as well as our ability to accomplish our strategic objectives.

In that event, the market price

of our common stock could decline and you could lose part or all of your investment.

Our actual results could differ materially from

1 unchanged sentence

The risks relating to our business set forth in our Prospectus, are set forth below and are unchanged substantively as of March

20, 2023, except for those risks designated by an asterisk (*).

20, 2023, except for those risks designated by an asterisk (*), which are significantly updated compared to the similar named risk factors

set forth in the Prospectus.

Additionally, those risks designated by a plus sign (+) represent new risk factors not included in the Prospectus.

In addition, the prior risk factor entitled “Jacob D.

Cohen, our Chairman and Chief Executive Officer, beneficially owns greater

than 50% of our outstanding shares of common stock, which causes us to be deemed a “controlled company” under the rules of

Nasdaq.” is no longer relevant or applicable to the Company.

in our common stock involves a high degree of risk.

14 unchanged sentences

and even if additional revenues are generated, there is no assurance that we can generate sufficient net income to support our operations.

As reflected in the accompanying financials, the Company had a net loss of $2,560,885 for the three months ended March 31, 2023 and an

accumulated deficit of $4,576,641 as of March 31, 2023.

As reflected in the accompanying financials, the Company had a net loss of $4,844,910 for the six months ended June 30, 2023 and an accumulated

deficit of $6,860,666 as of June 30, 2023.

Additionally, the Company had a net loss of $1,998,055 for the year ended December 31, 2022

10 unchanged sentences

its report on our financial statements as of December 31, 2022.

As of March 31, 2023, our current capital resources, combined with the

As of June 30, 2023, our current capital resources, combined with the

net proceeds from the offering, are expected to be sufficient for us to fund operations for the next 12 months.

33 unchanged sentences

our ability to continue as a going concern.(*)

need capital to support our operations and to commercialize our current Mango ED product.

need capital to support our operations and continue to market and commercialize our current Mango ED product.

We may also require additional funding in the

49 unchanged sentences

believe that our ability to compete depends upon many factors both within and beyond our control, including:

our marketing

the flexibility and variety

of our product offerings relative to our competitors, and our ability to timely launch new product initiatives;

the quality and price of

products offered by us and our competitors;

our reputation and brand

strength relative to our competitors;

customer satisfaction;

the size and composition

of our customer base;

the convenience of the

experience that we provide;

our ability to comply with,

and manage the costs of complying with, laws and regulations applicable to our business;

our ability to cost-effectively

source and distribute the products we offer and to manage our operation.

marketing efforts;

flexibility and variety of our product offerings relative to our competitors, and our ability to timely launch new product initiatives;

quality and price of products offered by us and our competitors;

reputation and brand strength relative to our competitors;

satisfaction;

size and composition of our customer base;

convenience of the experience that we provide;

ability to comply with, and manage the costs of complying with, laws and regulations applicable to our business;

ability to cost-effectively source and distribute the products we offer and to manage our operation.

competitors also have longer operating histories, and will have larger fulfillment infrastructures, greater technical capabilities, faster

41 unchanged sentences

have entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party, which entity is currently

licensed to provide pharmacy services in only 44 states.(*)

have entered into a Master Services Agreement and Statement of Work (SOW) for Epiq Scripts, a related party, 51% owned and controlled

licensed to provide pharmacy services in only 45 states and the District of Columbia.(*)

have entered into a Master Services Agreement and Statement of Work (SOW) for Epiq Scripts, a related party, 51% owned and

controlled by Jacob D.

Cohen, our Chairman and Chief Executive Officer, to provide us pharmacy and compounding services.

Epiq Scripts has filed

with the Utilization Review Accreditation Commission (“URAC”) to obtain its pharmacy accreditation and has State Board of

Pharmacy (or its equivalent) licenses in 44 states:

Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii,

Idaho, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Massachusetts, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada,

New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South

Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.

It is also in the process of applying

for additional state licenses and plans to eventually obtain licenses in all 50 states by the end of 2023, with some state licenses easier

to obtain and quicker to obtain than others.

As a result of the above, Epiq Scripts can currently only provide the Services to us in

the 44 states described above, and we will be unable to sell its products to any customers in any states other than those 44 states,

until Epiq Scripts is able to obtain licenses in other states and is limited to selling products to customers only in the states in which

Epiq Scripts holds licenses.

Scripts has filed with the Utilization Review Accreditation Commission (“URAC”) to obtain its pharmacy accreditation and

has State Board of Pharmacy (or its equivalent) licenses in 45 states and the District of Columbia:

Alaska, Arizona, Arkansas,

Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Massachusetts,

Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North

Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia,

Washington, West Virginia, Wisconsin, and Wyoming.

It is also in the process of applying for additional state licenses and plans to

eventually obtain licenses in all 50 states by the end of 2023, with some state licenses easier to obtain and quicker to obtain than

As a result of the above, Epiq Scripts can currently only provide the Services to us in the 45 states described above and

the District of Columbia, and we will be unable to sell its products to any customers in any states other than those 45 states and the District of Columbia,

until Epiq Scripts is able to obtain licenses in other states and is limited to selling products to customers only in the states in

which Epiq Scripts holds licenses.

Master Services Agreement does not address product liability claims which may result in us bringing legal claims or actions against Epiq

19 unchanged sentences

Mango ED product is prescribed by physicians pursuant to our agreement with BrighterMD, LLC doing business as Doctegrity (“ Doctegrity ”).

Epiq Scripts was only formed in January 2022, and to date has only recently began compounding drugs for patients.

Epiq Scripts was only formed in January 2022, and has only been compounding drugs for patients for a short period of time.

We face risks relying

63 unchanged sentences

actions in response to these conditions, such as price increases, could reduce consumer spending or change consumer purchasing habits.

performance depends significantly on factors that may affect the level and pattern of consumer spending in the markets in which we operate.

Such factors include consumer preference, consumer confidence, consumer income, consumer perception of the safety and quality of our

future products and shifts in the perceived value for our products relative to alternatives.

A general decline in the consumption of

our future products could occur at any time as a result of change in consumer preference, perception, confidence and spending habits,

including an unwillingness to pay a premium or an inability to purchase our products due to financial hardship or increased price sensitivity,

which may be exacerbated by the effects of the COVID-19 pandemic, inflationary pressures and economic uncertainty.

If consumer preferences

shift away from our future products, our business, financial condition and results of operations could be adversely affected.

success of our products depend on a number of factors including our ability to accurately anticipate changes in market demand and consumer

preferences, our ability to differentiate the quality of our future products from those of our competitors, and the effectiveness of

our marketing and advertising campaigns for our products.

We may not be successful in identifying trends in consumer preferences and

developing products that respond to such trends in a timely manner.

We also may not be able to effectively promote our products by our

marketing and advertising campaigns and gain market acceptance.

If our products fail to gain market acceptance, are restricted by regulatory

requirements or have quality problems, we may not be able to fully recover costs and expenses incurred in our operation, and our business,

financial condition, results of operations and prospects could be adversely affected.

rely upon independent third-party transportation providers for all of our product shipments and are subject to increased shipping costs

as well as the potential inability of our third-party transportation providers to deliver on a timely basis.

rely upon independent third-party transportation providers for all of our product shipments, including shipments from our related party

pharmacy to our customers.

Our utilization of these third party delivery services for shipments is subject to risks which may impact

a shipping company’s ability to provide delivery services that adequately meet our shipping needs, including risks related to employee

strikes, labor and capacity constraints, port security considerations, trade policy changes or restrictions, military conflicts, acts

of terrorism, accidents, natural disasters and inclement weather.

Any interruption in service provided by our shipping companies could

cause temporary disruptions in our business, a loss of sales and profits, and other material adverse effects.

In addition, we are subject

to increased shipping costs when fuel prices increase, as we use expedited means of transportation such as air freight.

the shipping company we use, we could face logistical difficulties that could adversely affect deliveries, and we would incur costs and

expend resources in connection with such change.

failure of our physician services provider, Doctegrity, to attract and retain physicians in a competitive labor market could limit our

ability to execute our growth strategy, resulting in a slower rate of growth.

wellness business will depend on the ability of our future contracted telemedicine services provider(s) to continue to recruit and retain

a sufficient number of qualified licensed doctors.

Although we expect such provider(s) will have an effective recruitment process, there

is no assurance that such provider(s) will be able to secure arrangements with sufficient numbers of licensed doctors or retain the services

of such practitioners.

If our provider(s) experience delays or shortages in obtaining access to qualified physicians, we would be unable

to operate and may be forced to seek alternative arrangements which could be more costly or may be forced to suspend our business operations.

we are unable to maintain or enter into future agreements with suppliers or our suppliers fail to supply us with our Mango ED product

ingredients or any other potential future men’s wellness products, we may experience delays in selling our products.(*)

may not be successful in maintaining or entering into new supply agreements on reasonable terms or at all or that we or our suppliers

will be able to obtain or maintain the necessary regulatory approvals or state and federal controlled substances registrations for current

or potential future suppliers in a timely manner or at all.

If we are unable to obtain a sufficient quantity of active pharmaceutical

ingredients manufactured at a facility that is registered and listed with the FDA and required to produce products, there could be a

delay in producing products, which could adversely affect our product sales and operating results materially, which could significantly

harm our business.

This has not occurred to date.

currently do not have any manufacturing facilities and intend to rely on third parties for the supply of our products (such as Epiq Scripts),

as well as for the supply of materials.

However, we cannot be certain that we or our suppliers will be able to obtain or maintain the

necessary regulatory approvals or registrations for these suppliers in a timely manner or at all.

business is exposed to risks associated with credit card and other online payment chargebacks and fraud.

majority of our revenue is, and is expected to be, processed through credit cards and other online payments.

If we experience refunds

or chargebacks, our processors could require us to create reserves, increase fees or terminate contracts with us, which would have an

adverse effect on our financial condition.

Our failure to limit fraudulent transactions conducted on our website, such as through the

use of stolen credit card numbers, could also subject us to liability and adversely impact our reputation.

Under credit card association

rules, penalties may be imposed at the discretion of the association for inadequate fraud protection.

Any such potential penalties would

be imposed on our credit card processor by the association.

However, we face the risk that we may fail to maintain an adequate level

of fraud protection and that one or more credit card associations or other processors may, at any time, assess penalties against us or

terminate our ability to accept credit card payments or other form of online payments from customers, which would have a material adverse

effect on our business, financial condition and operating results.

could also incur significant fines or lose our ability to give customers the option of using credit cards to pay for our products if

we fail to follow payment card industry data security standards, even if there is no compromise of customer information.

believe that we operate in compliance with payment card industry data security standards, it is possible that at times we may not be

in full compliance with these standards.

Accordingly, we could be fined, which could impact our financial condition, or our ability to

accept credit and debit cards as payment could be suspended, which would cause us to be unable to process payments using credit cards.

If we are unable to accept credit card payments, our business, financial condition and operating results may be adversely affected.

addition, we could be liable if there is a breach of the payment information.

Online commerce and communications depend on the secure

transmission of confidential information over public networks.

We rely on encryption and authentication technology to authenticate and

secure the transmission of confidential information, including cardholder information.

However, this technology may not prevent breaches

of the systems we use to protect cardholder information.

In addition, some of our contracting parties may also collect or possess information

about our customers, and we may be subject to litigation or our reputation may be harmed if our contracting parties fail to protect our

customers’ information or if they use it in a manner inconsistent with our policies and practices.

Data breaches can also occur

as a result of non-technical issues.

Under contracts with processors, if there is unauthorized access to, or disclosure of, credit card

information we store, we could be liable to the credit card issuing banks for their cost of issuing new cards and related expenses.

breaches, loss of data and other disruptions could compromise sensitive information related to our business or customers, or prevent

us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.

the ordinary course of our business, we collect, store, use and disclose sensitive data, including health information and other types

of personally identifiable information, or PII.

We also process and store, and use additional third parties to process and store, confidential

and proprietary information such as intellectual property and other proprietary business information, including that of our customers,

providers and contracting parties.

breaches of this infrastructure, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches,

and employee or contractor error, negligence or malfeasance, can create system disruptions, shutdowns or unauthorized disclosure or modifications

of information, causing sensitive, confidential or proprietary information to be accessed or acquired without authorization or to become

publicly available.

Because of the nature of the sensitive, confidential and proprietary information that we expect to collect, store,

transmit, and otherwise process, the security of our technology platform and other aspects of our services, including those provided

or facilitated by our third-party service providers, will be important to our operations and business strategy.

Measures taken to protect

our systems, those of our third-party service providers, or sensitive, confidential and proprietary information that we or our third-party

service providers process or maintain, may not adequately protect us from the risks associated with the collection, storage and transmission

of such information.

A security breach or privacy violation that leads to disclosure or unauthorized use or modification of, or that

prevents access to or otherwise impacts the confidentiality, security, or integrity of, sensitive, confidential, or proprietary information

we or our third-party service providers maintain or otherwise process, could harm our reputation, compel us to comply with breach notification

laws, and cause us to incur significant costs for remediation, fines, penalties, notification to individuals and governmental authorities,

implementation of measures intended to repair or replace systems or technology and to prevent future occurrences, potential increases

in insurance premiums, and forensic security audits or investigations.

As a result, a security breach or privacy violation could result

in increased costs or loss of revenue.

actual or suspected security breach or other compromise of our security measures or those of our third-party vendors, whether as a result

of hacking efforts, denial-of-service attacks, viruses, malicious software, break-ins, phishing attacks, social engineering or otherwise,

could harm our reputation and business, damage our brand and make it harder to retain existing customers or acquire new ones, require

us to expend significant capital and other resources to address the breach, and result in a violation of applicable laws, regulations

or other legal obligations.

Our insurance policies may not cover, or may not be adequate to reimburse us for, losses caused by any such

security breach.

rely on email and other messaging services to connect with our existing and potential customers.

Our customers may be targeted by parties

using fraudulent spoofing and phishing emails to misappropriate passwords, payment information or other personal information or to introduce

viruses through Trojan horse programs or otherwise through our customers’ computers, smartphones, tablets or other devices.

our efforts to mitigate the effectiveness of such malicious email campaigns through product improvements, spoofing and phishing may damage

our brand and increase our costs.

Any of these events or circumstances could materially adversely affect our business, financial condition

and operating results.

may experience fluctuations in our tax obligations and effective tax rate, which could adversely affect our business, results of operations,

and financial condition.

are subject to taxes in every jurisdiction in which we operate.

We record tax expense based on current tax liabilities and our estimates

of future tax liabilities, which may include reserves for estimates of probable settlements of tax audits.

At any one-time, multiple

tax years are subject to audit by various taxing jurisdictions.

The results of these audits and negotiations with taxing authorities

may affect the ultimate settlement of these issues.

Further, our effective tax rate in a given financial statement period may be materially

impacted by changes in tax laws, changes in the mix and level of earnings by taxing jurisdictions, or changes to existing accounting

rules or regulations.

Fluctuations in our tax obligations and effective tax rate could adversely affect our business, results of operations,

and financial condition.

we become subject to product liability claims, we may be required to pay damages that exceed our insurance coverage, if any.

products are subject to risks for product liability claims due to inherent potential side effects.

We may be unable to obtain or maintain

product liability coverage.

A product liability claim in excess of, or excluded from, our insurance coverage which currently covers exposure

to product liability claims, both technology products and physical products, would have to be paid out of cash reserves and could have

a material adverse effect upon our business, financial condition and results of operations.

Product liability insurance is expensive

even with large self-insured retentions or deductibles, difficult to maintain, and current or increased coverage may not continue to

be available on acceptable terms, if at all.

we cannot successfully defend ourselves against a product liability claim, we may incur substantial liabilities.

Regardless of merit

or eventual outcome, liability claims may result in:

to our reputation;

of defending the claim and/or related litigation;

of any potential adverse verdict;

monetary awards to patients or other claimants;

inability to commercialize our products.

awarded in a product liability action could be substantial and could have a negative impact on our financial condition.

Whether or not

we were ultimately successful in product liability litigation, such litigation would consume substantial amounts of our financial and

managerial resources, and might result in adverse publicity, all of which would impair our business.

example, a 2014 study published in The Journal of the American Medical Association determined that Sildenafil (the active ingredient

in Viagra) may be associated with a higher risk of developing melanoma.

The study evaluated data from more than 25,000 men who used Sildenafil

and found that Sildenafil use was significantly associated with an increased risk of subsequent melanoma, after considering other risk

It is possible that the ingredients we plan to use in our Mango ED product or any other products we sell in the future could

be found in the future to result in increases in the likelihood of developing cancer or other diseases, which could subject us to litigation,

penalties or recalls, all of which could have a material adverse effect on our operations and cause the value of our securities to decline

in value or become worthless.

in our data and information systems could harm our reputation and our ability to run our business.

rely extensively on data and information systems for our supply chain, financial reporting, human resources and various other operations,

processes and transactions.

Furthermore, a significant portion of the communications between us, our suppliers and customers depend on

information technology.

Our data and information systems are subject to damage or interruption from power outages, computer and telecommunications

failures, computer viruses, security breaches (including breaches of our transaction processing or other systems that could result in

the compromise of confidential customer data), catastrophic events, data breaches and usage errors by our employees or third-party service

Our data and information technology systems may also fail to perform as we anticipate, and we may encounter difficulties in

adapting these systems to changing technologies or expanding them to meet the future needs of our business.

If our systems are breached,

damaged or cease to function properly, we may have to make significant investments to fix or replace them, suffer interruptions in our

operations, incur liability to our customers and others or face costly litigation, and our reputation with our customers may be harmed.

We also rely on third parties for a majority of our data and information systems, including for third-party hosting and payment processing.

If these facilities fail, or if they suffer a security breach or interruption or degradation of service, a significant amount of our

data could be lost or compromised and our ability to operate our business and deliver our product offerings could be materially impaired.

In addition, various third parties, such as our suppliers and payment processors, also rely heavily on information technology systems,

and any failure of these systems could also cause loss of sales, transactional or other data and significant interruptions to our business.

Any material interruption in the data and information technology systems we rely on, including the data or information technology systems

of third parties, could materially adversely affect our business, financial condition and operating results.

Related to Legal, Regulatory and Government

incur significant costs to ensure compliance with U.S.

Our performance depends significantly

on factors that may affect the level and pattern of consumer spending in the markets in which we operate.

Such factors include consumer

preference, consumer confidence, consumer income, consumer perception of the safety and quality of our future products and shifts in the

perceived value for our products relative to alternatives.

A general decline in the consumption of our future products could occur at

any time as a result of change in consumer preference, perception, confidence and spending habits, including an unwillingness to pay a

premium or an inability to purchase our products due to financial hardship or increased price sensitivity, which may be exacerbated by

the effects of the COVID-19 pandemic, inflationary pressures and economic uncertainty.

If consumer preferences shift away from our future

products, our business, financial condition and results of operations could be adversely affected.

The success of our products depend

on a number of factors including our ability to accurately anticipate changes in market demand and consumer preferences, our ability to

differentiate the quality of our future products from those of our competitors, and the effectiveness of our marketing and advertising

campaigns for our products.

We may not be successful in identifying trends in consumer preferences and developing products that respond

to such trends in a timely manner.

We also may not be able to effectively promote our products by our marketing and advertising campaigns

and gain market acceptance.

If our products fail to gain market acceptance, are restricted by regulatory requirements or have quality

problems, we may not be able to fully recover costs and expenses incurred in our operation, and our business, financial condition, results

of operations and prospects could be adversely affected.

We rely upon independent

third-party transportation providers for all of our product shipments and are subject to increased shipping costs as well as the potential

inability of our third-party transportation providers to deliver on a timely basis.

We rely upon independent third-party

transportation providers for all of our product shipments, including shipments from our related party pharmacy to our customers.

Our utilization

of these third party delivery services for shipments is subject to risks which may impact a shipping company’s ability to provide

delivery services that adequately meet our shipping needs, including risks related to employee strikes, labor and capacity constraints,

port security considerations, trade policy changes or restrictions, military conflicts, acts of terrorism, accidents, natural disasters

and inclement weather.

Any interruption in service provided by our shipping companies could cause temporary disruptions in our business,

a loss of sales and profits, and other material adverse effects.

In addition, we are subject to increased shipping costs when fuel prices

increase, as we use expedited means of transportation such as air freight.

If we change the shipping company we use, we could face logistical

difficulties that could adversely affect deliveries, and we would incur costs and expend resources in connection with such change.

The failure of our physician

services provider, Doctegrity, to attract and retain physicians in a competitive labor market could limit our ability to execute our growth

strategy, resulting in a slower rate of growth.

Our wellness business will depend

on the ability of our future contracted telemedicine services provider(s) to continue to recruit and retain a sufficient number of qualified

licensed doctors.

Although we expect such provider(s) will have an effective recruitment process, there is no assurance that such provider(s)

will be able to secure arrangements with sufficient numbers of licensed doctors or retain the services of such practitioners.

If our provider(s)

experience delays or shortages in obtaining access to qualified physicians, we would be unable to operate and may be forced to seek alternative

arrangements which could be more costly or may be forced to suspend our business operations.

If we are unable to maintain

or enter into future agreements with suppliers or our suppliers fail to supply us with our Mango ED product ingredients or any other potential

future men’s wellness products, we may experience delays in selling our products.(*)

We may not be successful in maintaining

or entering into new supply agreements on reasonable terms or at all or that we or our suppliers will be able to obtain or maintain the

necessary regulatory approvals or state and federal controlled substances registrations for current or potential future suppliers in a

timely manner or at all.

If we are unable to obtain a sufficient quantity of active pharmaceutical ingredients manufactured at a facility

that is registered and listed with the FDA and required to produce products, there could be a delay in producing products, which could

adversely affect our product sales and operating results materially, which could significantly harm our business.

This has not occurred

We currently do not have any manufacturing

facilities and intend to rely on third parties for the supply of our products (such as Epiq Scripts), as well as for the supply of materials.

However, we cannot be certain that we or our suppliers will be able to obtain or maintain the necessary regulatory approvals or registrations

for these suppliers in a timely manner or at all.

Our business is exposed

to risks associated with credit card and other online payment chargebacks and fraud.

A majority of our revenue is,

and is expected to be, processed through credit cards and other online payments.

If we experience refunds or chargebacks, our processors

could require us to create reserves, increase fees or terminate contracts with us, which would have an adverse effect on our financial

Our failure to limit fraudulent transactions conducted on our website, such as through the use of stolen credit card numbers,

could also subject us to liability and adversely impact our reputation.

Under credit card association rules, penalties may be imposed

at the discretion of the association for inadequate fraud protection.

Any such potential penalties would be imposed on our credit card

processor by the association.

However, we face the risk that we may fail to maintain an adequate level of fraud protection and that one

or more credit card associations or other processors may, at any time, assess penalties against us or terminate our ability to accept

credit card payments or other form of online payments from customers, which would have a material adverse effect on our business, financial

condition and operating results.

We could also incur significant

fines or lose our ability to give customers the option of using credit cards to pay for our products if we fail to follow payment card

industry data security standards, even if there is no compromise of customer information.

Although we believe that we operate in compliance

with payment card industry data security standards, it is possible that at times we may not be in full compliance with these standards.

Accordingly, we could be fined, which could impact our financial condition, or our ability to accept credit and debit cards as payment

could be suspended, which would cause us to be unable to process payments using credit cards.

If we are unable to accept credit card payments,

our business, financial condition and operating results may be adversely affected.

In addition, we could be liable

if there is a breach of the payment information.

Online commerce and communications depend on the secure transmission of confidential

information over public networks.

We rely on encryption and authentication technology to authenticate and secure the transmission of confidential

information, including cardholder information.

However, this technology may not prevent breaches of the systems we use to protect cardholder

In addition, some of our contracting parties may also collect or possess information about our customers, and we may be subject

to litigation or our reputation may be harmed if our contracting parties fail to protect our customers’ information or if they use

it in a manner inconsistent with our policies and practices.

Data breaches can also occur as a result of non-technical issues.

Under contracts

with processors, if there is unauthorized access to, or disclosure of, credit card information we store, we could be liable to the credit

card issuing banks for their cost of issuing new cards and related expenses.

Security breaches, loss

of data and other disruptions could compromise sensitive information related to our business or customers, or prevent us from accessing

critical information and expose us to liability, which could adversely affect our business and our reputation.

In the ordinary course of our

business, we collect, store, use and disclose sensitive data, including health information and other types of personally identifiable

information, or PII.

We also process and store, and use additional third parties to process and store, confidential and proprietary information

such as intellectual property and other proprietary business information, including that of our customers, providers and contracting parties.

Security breaches of this infrastructure,

including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches, and employee or contractor error,

negligence or malfeasance, can create system disruptions, shutdowns or unauthorized disclosure or modifications of information, causing

sensitive, confidential or proprietary information to be accessed or acquired without authorization or to become publicly available.

of the nature of the sensitive, confidential and proprietary information that we expect to collect, store, transmit, and otherwise process,

the security of our technology platform and other aspects of our services, including those provided or facilitated by our third-party

service providers, will be important to our operations and business strategy.

Measures taken to protect our systems, those of our third-party

service providers, or sensitive, confidential and proprietary information that we or our third-party service providers process or maintain,

may not adequately protect us from the risks associated with the collection, storage and transmission of such information.

breach or privacy violation that leads to disclosure or unauthorized use or modification of, or that prevents access to or otherwise impacts

the confidentiality, security, or integrity of, sensitive, confidential, or proprietary information we or our third-party service providers

maintain or otherwise process, could harm our reputation, compel us to comply with breach notification laws, and cause us to incur significant

costs for remediation, fines, penalties, notification to individuals and governmental authorities, implementation of measures intended

to repair or replace systems or technology and to prevent future occurrences, potential increases in insurance premiums, and forensic

security audits or investigations.

As a result, a security breach or privacy violation could result in increased costs or loss of revenue.

Any actual or suspected security

breach or other compromise of our security measures or those of our third-party vendors, whether as a result of hacking efforts, denial-of-service

attacks, viruses, malicious software, break-ins, phishing attacks, social engineering or otherwise, could harm our reputation and business,

damage our brand and make it harder to retain existing customers or acquire new ones, require us to expend significant capital and other

resources to address the breach, and result in a violation of applicable laws, regulations or other legal obligations.

Our insurance policies

may not cover, or may not be adequate to reimburse us for, losses caused by any such security breach.

We rely on email and other messaging

services to connect with our existing and potential customers.

Our customers may be targeted by parties using fraudulent spoofing and

phishing emails to misappropriate passwords, payment information or other personal information or to introduce viruses through Trojan

horse programs or otherwise through our customers’ computers, smartphones, tablets or other devices.

Despite our efforts to mitigate

the effectiveness of such malicious email campaigns through product improvements, spoofing and phishing may damage our brand and increase

Any of these events or circumstances could materially adversely affect our business, financial condition and operating results.

As of the date of this filing, there have been no such data breaches or

other security related issues.

We may experience fluctuations

in our tax obligations and effective tax rate, which could adversely affect our business, results of operations, and financial condition.

We are subject to taxes in every

jurisdiction in which we operate.

We record tax expense based on current tax liabilities and our estimates of future tax liabilities,

which may include reserves for estimates of probable settlements of tax audits.

At any one-time, multiple tax years are subject to audit

by various taxing jurisdictions.

The results of these audits and negotiations with taxing authorities may affect the ultimate settlement

of these issues.

Further, our effective tax rate in a given financial statement period may be materially impacted by changes in tax laws,

changes in the mix and level of earnings by taxing jurisdictions, or changes to existing accounting rules or regulations.

in our tax obligations and effective tax rate could adversely affect our business, results of operations, and financial condition.

If we become subject to

product liability claims, we may be required to pay damages that exceed our insurance coverage, if any.

Our products are subject to risks

for product liability claims due to inherent potential side effects.

We may be unable to obtain or maintain product liability coverage.

A product liability claim in excess of, or excluded from, our insurance coverage which currently covers exposure to product liability

claims, both technology products and physical products, would have to be paid out of cash reserves and could have a material adverse effect

upon our business, financial condition and results of operations.

Product liability insurance is expensive even with large self-insured

retentions or deductibles, difficult to maintain, and current or increased coverage may not continue to be available on acceptable terms,

If we cannot successfully defend

ourselves against a product liability claim, we may incur substantial liabilities.

Regardless of merit or eventual outcome, liability

claims may result in:

injury to our reputation;

costs of defending the claim and/or related litigation;

cost of any potential adverse verdict;

substantial monetary awards to patients or other claimants;

the inability to commercialize our products.

Damages awarded in a product liability

action could be substantial and could have a negative impact on our financial condition.

Whether or not we were ultimately successful

in product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources, and might

result in adverse publicity, all of which would impair our business.

For example, a 2014 study published

in The Journal of the American Medical Association determined that Sildenafil (the active ingredient in Viagra) may be associated with

a higher risk of developing melanoma.

The study evaluated data from more than 25,000 men who used Sildenafil and found that Sildenafil

use was significantly associated with an increased risk of subsequent melanoma, after considering other risk factors.

It is possible that

the ingredients we plan to use in our Mango ED product or any other products we sell in the future could be found in the future to result

in increases in the likelihood of developing cancer or other diseases, which could subject us to litigation, penalties or recalls, all

of which could have a material adverse effect on our operations and cause the value of our securities to decline in value or become worthless.

Disruptions in our data

and information systems could harm our reputation and our ability to run our business.

We rely extensively on data and

information systems for our supply chain, financial reporting, human resources and various other operations, processes and transactions.

Furthermore, a significant portion of the communications between us, our suppliers and customers depend on information technology.

data and information systems are subject to damage or interruption from power outages, computer and telecommunications failures, computer

viruses, security breaches (including breaches of our transaction processing or other systems that could result in the compromise of confidential

customer data), catastrophic events, data breaches and usage errors by our employees or third-party service providers.

Our data and information

technology systems may also fail to perform as we anticipate, and we may encounter difficulties in adapting these systems to changing

technologies or expanding them to meet the future needs of our business.

If our systems are breached, damaged or cease to function properly,

we may have to make significant investments to fix or replace them, suffer interruptions in our operations, incur liability to our customers

and others or face costly litigation, and our reputation with our customers may be harmed.

We also rely on third parties for a majority

of our data and information systems, including for third-party hosting and payment processing.

If these facilities fail, or if they suffer

a security breach or interruption or degradation of service, a significant amount of our data could be lost or compromised and our ability

to operate our business and deliver our product offerings could be materially impaired.

In addition, various third parties, such as our

suppliers and payment processors, also rely heavily on information technology systems, and any failure of these systems could also cause

loss of sales, transactional or other data and significant interruptions to our business.

Any material interruption in the data and information

technology systems we rely on, including the data or information technology systems of third parties, could materially adversely affect

our business, financial condition and operating results.

Risks Related to Legal, Regulatory and Government

We incur significant costs

to ensure compliance with U.S.

and Nasdaq reporting and corporate governance requirements.

incur significant costs associated with our public company reporting requirements and with applicable U.S.

and Nasdaq corporate governance

requirements, including requirements under the Sarbanes-Oxley Act of 2002 and other rules implemented by the SEC and Nasdaq.

all of these applicable rules and regulations to significantly increase our legal and financial compliance costs and to make some activities

more time consuming and costly.

We also expect that these applicable rules and regulations may make it more difficult and more expensive

for us to retain director and officer liability insurance and we may be required to accept reduced policy limits and coverage or incur

substantially higher costs to obtain the same or similar coverage.

As a result, it may be more difficult for us to attract and retain

qualified individuals to serve on our Board of Directors or as executive officers.

we fail to comply with government laws and regulations it could have a materially adverse effect on our business.

health care industry is subject to extensive federal, state and local laws and regulations relating to licensure, conduct of operations,

ownership of facilities, addition of facilities and services, payment for services and prices for services that are extremely complex

and for which, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation.

care in structuring our arrangements with physicians and other referral sources to attempt to comply in all material respects with applicable

We also take such laws into account when planning future marketing and other activities, and expect that our operations will be

in compliance with applicable law.

We incur significant costs associated

with our public company reporting requirements and with applicable U.S.

and Nasdaq corporate governance requirements, including requirements

under the Sarbanes-Oxley Act of 2002 and other rules implemented by the SEC and Nasdaq.

We expect all of these applicable rules and regulations

to significantly increase our legal and financial compliance costs and to make some activities more time consuming and costly.

expect that these applicable rules and regulations may make it more difficult and more expensive for us to retain director and officer

liability insurance and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain

the same or similar coverage.

As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our

Board of Directors or as executive officers.

If we fail to comply with

government laws and regulations it could have a materially adverse effect on our business.

The health care industry is subject

to extensive federal, state and local laws and regulations relating to licensure, conduct of operations, ownership of facilities, addition

of facilities and services, payment for services and prices for services that are extremely complex and for which, in many instances,

the industry does not have the benefit of significant regulatory or judicial interpretation.

We exercise care in structuring our arrangements

with physicians and other referral sources to attempt to comply in all material respects with applicable laws.

We also take such laws

into account when planning future marketing and other activities, and expect that our operations will be in compliance with applicable

The laws, rules and regulations described above are complex and subject to interpretation.

event of a determination that we are in violation of such laws, rules or regulations, or if further changes in the regulatory framework

occur, any such determination or changes could have a material adverse effect on our business.

There can be no assurance however that

we will not be found in noncompliance in any particular situation.

Federal law limits compounded drugs that are “essentially copies” of commercially available FDA approved drugs, including

those with the same route of administration.

If our Mango ED product, or any future products we may choose to market in the future are

deemed to be “essentially copies” of commercially available FDA approved drugs we would be prohibited from compounding such

drugs and would be unable to sell our Mango ED drug or future products.

If that were to occur, we would need to change our business plan

which would require substantial additional expenses and would have a material adverse effect on our cash flows and the value of our securities.

activities for our Mango ED product are subject to strict governmental regulation which may limit our ability to market or promote such

business model depends on qualifying for certain statutory exemptions for drugs that are compounded by pharmacies in accordance with

applicable requirements.

Pharmacy compounding is also subject to state oversight and regulation.

Federal requirements include obtaining

individual prescriptions establishing that the compounded drug is necessary for each drug prescribed for each of our customers.

law also limits compounded drugs that are “essentially copies” of commercially available FDA approved drugs, including those

with the same route of administration.

These restrictions will limit our ability to market compounded drugs that have the same active

ingredients and route of administration as FDA-approved drugs, unless the compounded version offers a significant difference that the

prescriber determines is necessary for each individual patient.

FDA also has the authority to impose significant restrictions on approved products through regulations on advertising, promotional and

distribution activities.

In particular, the FDA will object to any promotional activity (including through testimonials and surrogates)

that is “false or misleading in any particular,” including the failure to disclose material facts.

For example, the FDA will

expect adequate substantiation for an efficacy claim, which would require substantial evidence derived from adequate and well-controlled

clinical trials.

We believe we can conduct truthful and non-misleading promotional activities, including activities involving the use

of testimonials and surrogates, with limited claims that do not require substantial evidence derived from adequate and well-controlled

clinical trials and which do not include efficacy claims.

If our products (including our Mango ED product) are marketed in contradiction

with FDA laws and regulations, the FDA may issue warning letters that require specific remedial measures to be taken, as well as an immediate

cessation of the impermissible conduct, resulting in adverse publicity.

The FDA may also require that all future promotional materials

receive prior agency review and approval before use.

Certain states have also adopted regulations and reporting requirements surrounding

the promotion of pharmaceuticals.

Failure by us or any of our collaborators to comply with state requirements may affect our ability

to promote or sell future products in certain states.

This, in turn, could have a material adverse impact on our financial results and

financial condition and could subject us to significant liability, including civil and administrative remedies as well as criminal sanctions.

restrictions may be more burdensome for compounded products as compared with FDA approved products because the latter have substantial

evidence of safety and effectiveness, which will limit our ability to compete against the sale of comparable FDA-approved products.

government regulations and enforcement activities may require increased costs or adversely affect our results of operations.

operations may be subject to direct and indirect adoption, expansion or reinterpretation of various laws and regulations.

with these evolving laws, regulations and interpretations may require us to change our practices at an undeterminable and possibly significant

initial monetary and annual expense.

These additional monetary expenditures may increase future overhead, which could have a material

adverse effect on our results of operations.

There could also be laws and regulations applicable to our business that we have not identified

or that, if changed, may be costly to us, and we cannot predict all the ways in which implementation of such laws and regulations may

Additionally,

the introduction of new products may require us to comply with additional, yet undetermined, laws and regulations.

Compliance may require

obtaining appropriate federal, state, or local licenses or certificates, increasing our security measures and expending additional resources

to monitor developments in applicable rules and ensure compliance.

The failure to adequately comply with these future laws and regulations

may delay or possibly prevent our products from being offered to customers, which could have a material adverse effect on our business,

financial condition, and results of operations.

to comply with federal, state and foreign laws and regulations relating to privacy, data protection and consumer protection, or the expansion

of current or the enactment of new laws or regulations relating to privacy, data protection and consumer protection, could adversely

affect our business and our financial condition.

variety of federal, state and foreign laws and regulations govern the collection, use, retention, sharing and security of consumer data.

Laws and regulations relating to privacy, data protection and consumer protection are evolving and subject to potentially differing interpretations.

These requirements may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another or may conflict with

other rules or our practices.

In the event of a determination that we

are in violation of such laws, rules or regulations, or if further changes in the regulatory framework occur, any such determination or

changes could have a material adverse effect on our business.

There can be no assurance however that we will not be found in noncompliance

in any particular situation.

Separately, Federal law limits

compounded drugs that are “essentially copies” of commercially available FDA approved drugs, including those with the same

route of administration.

If our Mango ED product, or any future products we may choose to market in the future are deemed to be “essentially

copies” of commercially available FDA approved drugs we would be prohibited from compounding such drugs and would be unable to sell

our Mango ED drug or future products.

If that were to occur, we would need to change our business plan which would require substantial

additional expenses and would have a material adverse effect on our cash flows and the value of our securities.

Marketing activities for

our Mango ED product are subject to strict governmental regulation which may limit our ability to market or promote such product.

Our business model depends on

qualifying for certain statutory exemptions for drugs that are compounded by pharmacies in accordance with applicable requirements.

compounding is also subject to state oversight and regulation.

Federal requirements include obtaining individual prescriptions establishing

that the compounded drug is necessary for each drug prescribed for each of our customers.

Federal law also limits compounded drugs that

are “essentially copies” of commercially available FDA approved drugs, including those with the same route of administration.

These restrictions will limit our ability to market compounded drugs that have the same active ingredients and route of administration

as FDA-approved drugs, unless the compounded version offers a significant difference that the prescriber determines is necessary for each

individual patient.

The FDA also has the authority

to impose significant restrictions on approved products through regulations on advertising, promotional and distribution activities.

particular, the FDA will object to any promotional activity (including through testimonials and surrogates) that is “false or misleading

in any particular,” including the failure to disclose material facts.

For example, the FDA will expect adequate substantiation for

an efficacy claim, which would require substantial evidence derived from adequate and well-controlled clinical trials.

We believe we can

conduct truthful and non-misleading promotional activities, including activities involving the use of testimonials and surrogates, with

limited claims that do not require substantial evidence derived from adequate and well-controlled clinical trials and which do not include

efficacy claims.

If our products (including our Mango ED product) are marketed in contradiction with FDA laws and regulations, the FDA

may issue warning letters that require specific remedial measures to be taken, as well as an immediate cessation of the impermissible

conduct, resulting in adverse publicity.

The FDA may also require that all future promotional materials receive prior agency review and

approval before use.

Certain states have also adopted regulations and reporting requirements surrounding the promotion of pharmaceuticals.

Failure by us or any of our collaborators to comply with state requirements may affect our ability to promote or sell future products

in certain states.

This, in turn, could have a material adverse impact on our financial results and financial condition and could subject

us to significant liability, including civil and administrative remedies as well as criminal sanctions.

These restrictions may be more

burdensome for compounded products as compared with FDA approved products because the latter have substantial evidence of safety and effectiveness,

which will limit our ability to compete against the sale of comparable FDA-approved products.

Evolving government regulations

and enforcement activities may require increased costs or adversely affect our results of operations.

Our operations may be subject

to direct and indirect adoption, expansion or reinterpretation of various laws and regulations.

Compliance with these evolving laws, regulations

and interpretations may require us to change our practices at an undeterminable and possibly significant initial monetary and annual expense.

These additional monetary expenditures may increase future overhead, which could have a material adverse effect on our results of operations.

There could also be laws and regulations applicable to our business that we have not identified or that, if changed, may be costly to

us, and we cannot predict all the ways in which implementation of such laws and regulations may affect us.

Additionally, the introduction

of new products may require us to comply with additional, yet undetermined, laws and regulations.

Compliance may require obtaining appropriate

federal, state, or local licenses or certificates, increasing our security measures and expending additional resources to monitor developments

in applicable rules and ensure compliance.

The failure to adequately comply with these future laws and regulations may delay or possibly

prevent our products from being offered to customers, which could have a material adverse effect on our business, financial condition,

and results of operations.

Failure to comply with federal,

state and foreign laws and regulations relating to privacy, data protection and consumer protection, or the expansion of current or the

enactment of new laws or regulations relating to privacy, data protection and consumer protection, could adversely affect our business

and our financial condition.(*)

A variety of federal, state and

foreign laws and regulations govern the collection, use, retention, sharing and security of consumer data.

Laws and regulations relating

to privacy, data protection and consumer protection are evolving and subject to potentially differing interpretations.

These requirements

may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another or may conflict with other rules or our

As a result, our practices may not comply with all such laws, regulations, requirements and obligations.

Any failure, or perceived failure, by us to comply with any federal, state or foreign privacy or consumer protection-related laws, regulations,

industry self-regulatory principles, industry standards or codes of conduct, regulatory guidance, orders to which we may be subject or

other legal obligations relating to privacy or consumer protection could adversely affect our reputation, brand and business, and may

result in claims, investigations, proceedings or actions against us by governmental entities or others or other liabilities or require

us to change our operations.

collect, store, process, and use personal information and other customer data, and will rely on third parties that are not directly under

our control to manage certain of these operations and to collect, store, process and use payment information.

Our customers’ personal

information may include names, addresses, phone numbers, email addresses, payment card data, and payment account information, as well

as other information.

Due to the volume and sensitivity of the personal information and data we and these third parties manage, the security

features of our information systems are critical.

If our security measures, some of which are managed by third parties, are breached

or fail, unauthorized persons may be able to access sensitive customer data, including payment card data.

If we or our independent service

providers or business partners experience a breach of systems that collect, store or process our members’ and customers’

sensitive data, our brand could be harmed, sales of our products could decrease, and we could be exposed to claims, losses, administrative

fines, litigation or regulatory and governmental investigations and proceedings.

Any such claim, investigation, proceeding or action

could hurt our reputation, brand and business, force us to incur significant expenses in defense of such proceedings, distract our management,

increase our costs of doing business, result in a loss of customers and suppliers and may result in the imposition of monetary penalties

and administrative fines.

Depending on the nature of the information compromised, we may also have obligations to notify users, law enforcement,

or payment companies about the incident and may need to provide some form of remedy, such as refunds, for the individuals affected by

the incident.

laws, rules, and regulations are constantly evolving in the United States and abroad and may be inconsistent from one jurisdiction to

We expect that new industry standards, laws and regulations will continue to be proposed regarding privacy, data protection

and information security in many jurisdictions, including the California Consumer Privacy Act of 2018, which went effective January 1,

2020, the California Consumer Privacy Rights Act, which goes effective on January 1, 2023, the Colorado Privacy Act, which goes effective

on July 1, 2013, the Virginia Consumer Data Protection Act, which went into effective on January 1, 2023, the Connecticut Personal Data

Privacy and Online Monitoring Act which goes effective July 1, 2023, the Iowa Consumer Data Protection Act which goes effective January

1, 2025, and the Utah Consumer Privacy Act which goes effective December 31, 2023.

We cannot yet determine the impact such future laws,

regulations and standards may have on our business.

Complying with these evolving obligations is costly.

For instance, expanding definitions

and interpretations of what constitutes “ personal data ” (or the equivalent) within the United States and elsewhere

may increase our compliance costs.

Any failure to comply could give rise to unwanted media attention and other negative publicity, damage

our customer and consumer relationships and reputation, and result in lost sales, claims, administrative fines, lawsuits or regulatory

and governmental investigations and proceedings and may harm our business and results of operations.

Mango ED product has not been, and will not be, approved by the FDA.

The use of such product may cause serious side effects which could

subject us to material litigation, damages and penalties.

Mango ED product has not been, and will not be, approved by the FDA.

It will be compounded using bulk drug substances and as such, will

be exempt from specific FDA approval, provided that it is compounded in accordance with statutory requirements.

Because compounded drugs

are not FDA-approved, the FDA does not verify their safety, effectiveness, or quality before they are marketed.

In addition, poor compounding

practices can result in serious drug quality problems, such as contamination or a drug that contains too much or too little active ingredient,

among other possible quality deficiencies.

are not aware of any clinical studies involving the administration of tadalafil sublingually at the doses we intend to provide patients,

or the compounding of tadalafil, oxytocin, and L-arginine to treat ED, as is contemplated by our ED product.

Because our ED product has

not been, and will not be, approved by the FDA our product has not had the benefit of the FDA’s clinical trial protocol which seeks

to prevent the possibility of serious patient injury and death.

If this were to occur, we could be subject to litigation and governmental

action, which could result in costly litigation, significant fines, judgments or penalties.

For example, in October 2012, a pharmacy

in Massachusetts shipped compounded drugs that were contaminated with a fungus throughout the country, and these drugs were injected

into patients’ spines and joints.

More than 750 people in 20 states developed fungal infections, and more than 60 people died.

This type of action could have a significant negative impact on our brand name, results of operations and cash flows, and result in us

having to cease selling products, curtailing our business plan, or seeking bankruptcy protection.

main ingredients of our Mango ED product are publicly disclosed and separately our Mango ED product is being specially compounded for

the customer by a pharmacist with a physician’s prescription, and as a result, our Mango ED product formula can be replicated by

other companies.

Mango ED product is made up of the following three ingredients:

Tadalafil (10 milligrams (mg)) (the active ingredient in Cialis) and

Oxytocin (100 international units (IU)), which are used in FDA approved drugs;

and L-Arginine (50mg), an amino acid that is available

as a dietary supplement.

However, the fact that Tadalafil and Oxytocin are used in FDA approved drugs, and L-arginine is available as

a dietary supplement, does not mean that these ingredients will prove safe when combined into a single formulation to treat ED.

offer two dosage levels of our Mango ED product and anticipate a prescribing doctor prescribing a dosage based on the needs and medical

history of the patient.

Additionally, because our Mango ED product is being specially compounded for the customer by a pharmacist with

a physician’s prescription and because the ingredients for our Mango ED product will be publicly disclosed, this product formula

can be replicated by other companies.

As a result, competitors, including those with greater resources, marketing, and brand recognition,

may compete against us in the future using our exact product ingredients or variations thereof.

We may be unable to distinguish our Mango

ED product from copycat products and may not be able to differentiate our product from competitors in the marketplace.

As a result, we

may fail to obtain a significant market share, or may lose any market share we may obtain in the future, may be unable to compete with

competitors, and may be forced to abandon or curtail our business plan, which could cause the value of our shares to decline in value

or become worthless.

ED product needs to be compounded by licensed pharmacists who are subject to risks regarding applicable exemptions from the Federal Food,

Drug, and Cosmetic Act.

503A of the FFDCA describes the conditions under which compounded human drug products are exempt from the FFDCA sections on FDA approval

prior to marketing, current good manufacturing practice (“ cGMP ”) requirements, and labeling with adequate directions

One of these conditions is that the drugs must be compounded based on the receipt of valid patient-specific prescriptions.

ED product needs to be compounded by licensed pharmacists, after being prescribed by a licensed physician.

Licensed pharmacists who compound

drug products in accordance with Section 503A of the FFDCA are not required to comply with CGMP requirements and the drugs that they

compound are not required to be approved by the FDA, provided that the compounding complies with applicable requirements.

the FDA is often not aware of potential problems with compounded drug products or compounding practices unless it receives a complaint,

such as a report of a serious adverse event or visible contamination.

As such, the compounding of our products will be subject to limited

FDA oversight, which could lead to such products not being compounded safely and could lead to product recalls and litigation which could

have a significant negative impact on our brand name, results of operations and cash flows, and result in us having to cease selling

products, curtailing our business plan, or seeking bankruptcy protection.

Neither we, nor our representatives have had any conversations

with the FDA staff regarding whether our Mango ED product can be sold pursuant to Section 503A of the FFDCA Act and future conversations

with the FDA may result in the FDA staff raising issues with such sales pursuant to Section 503A of the FFDCA, requiring certain pre-requisites

or changes to our current business plan, which may be costly or time consuming, and/or may result in us being prohibited from selling

our Mango ED product pursuant to Section 503A of the FFDCA Act.

We also face risks that the compounding of our products does not fall

within the exemption from the FFDCA provided by Section 503A thereof.

For example, if the FDA determined that any of our products are

essentially a copy of an FDA approved product, we would be severely limited in our ability to compound such a product.

If any of the

above were to apply, we may need to change our business plan or compounding activities, which could force us to curtail our business

plan or expend significant additional resources to obtain FFDCA or FDA approval for our products.

Notwithstanding

the above, under relevant FDA guidance, the FDA generally does not consider a compounded drug to be “essentially a copy”

of a commercially available drug if the compounded drug has a different route of administration as compared with the approved alternative,

and we anticipate that our Mango ED product will be for a different route of administration (e.g., sublingual).

In addition, we do not

expect that we will be deemed to have engaged in such “copying”, because our Mango ED product is based on a prescriber’s

determination for each patient that the change associated with the compounded product (our Mango ED product) produces for the patient

a significant difference as compared with the commercially available drug product.

Under relevant FDA guidance, the FDA does not consider

a compounded drug “essentially a copy” if a prescriber determines that there is a change, made for an identified individual

patient, which produces for that patient a significant difference from the commercially available product.

care services, including arrangements with health care professionals, are heavily regulated at the state level, and the laws and regulations

may be changed or subject to new interpretations.

state separately licenses health care professionals and determines when and under what conditions they may interact with and provide

services to patients.

Telehealth consultations initiated through our platform must be offered in accordance with the laws and regulations

of the state where a patient is located, which may include laws that restrict the corporate practice of medicine and fee splitting.

state’s laws are subject to legislative and regulatory changes, as well as judicial interpretations, and future changes or interpretations

of state laws restricting the corporate practice of medicine and fee splitting could adversely affect the permissibility of (a) our relationship

with Doctegrity;

Any failure, or perceived

failure, by us to comply with any federal, state or foreign privacy or consumer protection-related laws, regulations, industry self-regulatory

principles, industry standards or codes of conduct, regulatory guidance, orders to which we may be subject or other legal obligations

relating to privacy or consumer protection could adversely affect our reputation, brand and business, and may result in claims, investigations,

proceedings or actions against us by governmental entities or others or other liabilities or require us to change our operations.

We collect, store, process, and

use personal information and other customer data, and will rely on third parties that are not directly under our control to manage certain

of these operations and to collect, store, process and use payment information.

Our customers’ personal information may include

names, addresses, phone numbers, email addresses, payment card data, and payment account information, as well as other information.

to the volume and sensitivity of the personal information and data we and these third parties manage, the security features of our information

systems are critical.

If our security measures, some of which are managed by third parties, are breached or fail, unauthorized persons

may be able to access sensitive customer data, including payment card data.

If we or our independent service providers or business partners

experience a breach of systems that collect, store or process our members’ and customers’ sensitive data, our brand could

be harmed, sales of our products could decrease, and we could be exposed to claims, losses, administrative fines, litigation or regulatory

and governmental investigations and proceedings.

Any such claim, investigation, proceeding or action could hurt our reputation, brand

and business, force us to incur significant expenses in defense of such proceedings, distract our management, increase our costs of doing

business, result in a loss of customers and suppliers and may result in the imposition of monetary penalties and administrative fines.

Depending on the nature of the information compromised, we may also have obligations to notify users, law enforcement, or payment companies

about the incident and may need to provide some form of remedy, such as refunds, for the individuals affected by the incident.

Privacy laws, rules, and regulations are constantly evolving in the United

States and abroad and may be inconsistent from one jurisdiction to another.

We expect that new industry standards, laws and regulations

will continue to be proposed regarding privacy, data protection and information security in many jurisdictions, including the California

Consumer Privacy Act of 2018, which went effective January 1, 2020, the California Consumer Privacy Rights Act, which went effective on

January 1, 2023, the Colorado Privacy Act, which went effective on July 1, 2013, the Virginia Consumer Data Protection Act, which went

into effective on January 1, 2023, the Connecticut Personal Data Privacy and Online Monitoring Act which went effective July 1, 2023,

the Iowa Consumer Data Protection Act which goes effective January 1, 2025, the Indiana Consumer Data Protection Act, which goes effective

January 1, 2026;

the Iowa Consumer Data Protection Act, which goes effective January 1, 2025;

the Montana Consumer Data Privacy Act, which

goes effective October 1, 2024;

the Tennessee Information Protection Act, which goes effective July 1, 2025;

the Texas Data Privacy and

Security Act, which goes effective July 1, 2025 and the Utah Consumer Privacy Act which goes effective December 31, 2023.

We cannot yet

determine the impact such future laws, regulations and standards may have on our business.

Complying with these evolving obligations is

For instance, expanding definitions and interpretations of what constitutes “ personal data ” (or the equivalent)

within the United States and elsewhere may increase our compliance costs.

Any failure to comply could give rise to unwanted media attention

and other negative publicity, damage our customer and consumer relationships and reputation, and result in lost sales, claims, administrative

fines, lawsuits or regulatory and governmental investigations and proceedings and may harm our business and results of operations.

Our Mango ED product has

not been, and will not be, approved by the FDA.

The use of such product may cause serious side effects which could subject us to material

litigation, damages and penalties.

Our Mango ED product has not been,

and will not be, approved by the FDA.

It will be compounded using bulk drug substances and as such, will be exempt from specific FDA approval,

provided that it is compounded in accordance with statutory requirements.

Because compounded drugs are not FDA-approved, the FDA does

not verify their safety, effectiveness, or quality before they are marketed.

In addition, poor compounding practices can result in serious

drug quality problems, such as contamination or a drug that contains too much or too little active ingredient, among other possible quality

deficiencies.

We are not aware of any clinical

studies involving the administration of tadalafil sublingually at the doses we intend to provide patients, or the compounding of tadalafil,

oxytocin, and L-arginine to treat ED, as is contemplated by our ED product.

Because our ED product has not been, and will not be, approved

by the FDA our product has not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious

patient injury and death.

If this were to occur, we could be subject to litigation and governmental action, which could result in costly

litigation, significant fines, judgments or penalties.

For example, in October 2012, a pharmacy in Massachusetts shipped compounded drugs

that were contaminated with a fungus throughout the country, and these drugs were injected into patients’ spines and joints.

than 750 people in 20 states developed fungal infections, and more than 60 people died.

This type of action could have a significant negative

impact on our brand name, results of operations and cash flows, and result in us having to cease selling products, curtailing our business

plan, or seeking bankruptcy protection.

The main ingredients of

our Mango ED product are publicly disclosed and separately our Mango ED product is being specially compounded for the customer by a pharmacist

with a physician’s prescription, and as a result, our Mango ED product formula can be replicated by other companies.

Our Mango ED product is made up

of the following three ingredients:

Tadalafil (10 milligrams (mg)) (the active ingredient in Cialis) and Oxytocin (100 international units

(IU)), which are used in FDA approved drugs;

and L-Arginine (50mg), an amino acid that is available as a dietary supplement.

the fact that Tadalafil and Oxytocin are used in FDA approved drugs, and L-arginine is available as a dietary supplement, does not mean

that these ingredients will prove safe when combined into a single formulation to treat ED.

We currently offer two dosage levels of our

Mango ED product and anticipate a prescribing doctor prescribing a dosage based on the needs and medical history of the patient.

Additionally,

because our Mango ED product is being specially compounded for the customer by a pharmacist with a physician’s prescription and

because the ingredients for our Mango ED product will be publicly disclosed, this product formula can be replicated by other companies.

As a result, competitors, including those with greater resources, marketing, and brand recognition, may compete against us in the future

using our exact product ingredients or variations thereof.

We may be unable to distinguish our Mango ED product from copycat products

and may not be able to differentiate our product from competitors in the marketplace.

As a result, we may fail to obtain a significant

market share, or may lose any market share we may obtain in the future, may be unable to compete with competitors, and may be forced to

abandon or curtail our business plan, which could cause the value of our shares to decline in value or become worthless.

Our ED product needs to

be compounded by licensed pharmacists who are subject to risks regarding applicable exemptions from the Federal Food, Drug, and Cosmetic

Section 503A of the FFDCA describes

the conditions under which compounded human drug products are exempt from the FFDCA sections on FDA approval prior to marketing, current

good manufacturing practice (“ cGMP ”) requirements, and labeling with adequate directions for use.

One of these conditions

is that the drugs must be compounded based on the receipt of valid patient-specific prescriptions.

Our ED product needs to be compounded

by licensed pharmacists, after being prescribed by a licensed physician.

Licensed pharmacists who compound drug products in accordance

with Section 503A of the FFDCA are not required to comply with CGMP requirements and the drugs that they compound are not required to

be approved by the FDA, provided that the compounding complies with applicable requirements.

Therefore, the FDA is often not aware of

potential problems with compounded drug products or compounding practices unless it receives a complaint, such as a report of a serious

adverse event or visible contamination.

As such, the compounding of our products will be subject to limited FDA oversight, which could

lead to such products not being compounded safely and could lead to product recalls and litigation which could have a significant negative

impact on our brand name, results of operations and cash flows, and result in us having to cease selling products, curtailing our business

plan, or seeking bankruptcy protection.

Neither we, nor our representatives have had any conversations with the FDA staff regarding whether

our Mango ED product can be sold pursuant to Section 503A of the FFDCA Act and future conversations with the FDA may result in the FDA

staff raising issues with such sales pursuant to Section 503A of the FFDCA, requiring certain pre-requisites or changes to our current

business plan, which may be costly or time consuming, and/or may result in us being prohibited from selling our Mango ED product pursuant

to Section 503A of the FFDCA Act.

We also face risks that the compounding of our products does not fall within the exemption from the

FFDCA provided by Section 503A thereof.

For example, if the FDA determined that any of our products are essentially a copy of an FDA approved

product, we would be severely limited in our ability to compound such a product.

If any of the above were to apply, we may need to change

our business plan or compounding activities, which could force us to curtail our business plan or expend significant additional resources

to obtain FFDCA or FDA approval for our products.

Notwithstanding the above, under

relevant FDA guidance, the FDA generally does not consider a compounded drug to be “essentially a copy” of a commercially

available drug if the compounded drug has a different route of administration as compared with the approved alternative, and we anticipate

that our Mango ED product will be for a different route of administration (e.g., sublingual).

In addition, we do not expect that we will

be deemed to have engaged in such “copying”, because our Mango ED product is based on a prescriber’s determination for

each patient that the change associated with the compounded product (our Mango ED product) produces for the patient a significant difference

as compared with the commercially available drug product.

Under relevant FDA guidance, the FDA does not consider a compounded drug “essentially

a copy” if a prescriber determines that there is a change, made for an identified individual patient, which produces for that patient

a significant difference from the commercially available product.

Health care services, including

arrangements with health care professionals, are heavily regulated at the state level, and the laws and regulations may be changed or

subject to new interpretations.

Each state separately licenses

health care professionals and determines when and under what conditions they may interact with and provide services to patients.

consultations initiated through our platform must be offered in accordance with the laws and regulations of the state where a patient

is located, which may include laws that restrict the corporate practice of medicine and fee splitting.

Each state’s laws are subject

to legislative and regulatory changes, as well as judicial interpretations, and future changes or interpretations of state laws restricting

the corporate practice of medicine and fee splitting could adversely affect the permissibility of (a) our relationship with Doctegrity;

and/or (b) Doctegrity’s relationship with its contracted physicians.

If our relationship with Doctegrity and/or

Doctegrity’s relationship with its contracted physicians needed to be restructured in light of any such adverse changes or interpretations,

that restructuring could negatively affect our ability to connect consumers with medical providers in certain states, and thus those

customers’ ability to ultimately receive our products.

do not have a pharmacy and depend on a related party to compound our Mango product and other potential future men’s wellness products.

rely on a related party pharmacy for the manufacture of our Mango product and will rely on this pharmacy or others for any potential

future men’s wellness products we market and we cannot assure you that they will be successful.

This subjects us to a number of

risks, including the following:

may not be able to control the commercialization of our products, including the amount, timing and quality of resources that our

contracting parties may devote to our products;

contracting parties may experience financial, regulatory or operational difficulties, which may impair their ability to fulfill their

contractual obligations;

combinations or significant changes in a contracting parties’ business strategy may adversely affect a contracting party’s

willingness or ability to perform their obligations under any arrangement;

disputes or disagreements may occur with one or more of our contracting parties or between our contracting parties and our suppliers

or former contracting parties;

contracting party could independently move forward with a competing product developed either independently or in collaboration with

others, including with one of our competitors.

any of our contracting parties fail to fulfill their future contractual obligations, our business may be negatively affected and we may

receive limited or no revenues under our agreements with them.

See also the risk factor, “ The related party pharmacy we have

entered into an agreement with may not receive licenses in all of the 50 United States to provide national coverage for us to sell our

Mango ED product and future products ” below.

use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and

security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in

significant liability or reputational harm and, in turn, a material adverse effect on our client base and revenue.

state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability and

integrity of personally identifiable information, or PII, including protected health information, or PHI.

These laws and regulations

include the Health Information Portability and Accountability Act of 1996 (“HIPAA”), as amended by the Health Information

Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations (referred to collectively as “HIPAA”).

HIPAA establishes a set of basic national privacy and security standards for the protection of PHI.

HIPAA requires us to develop and

maintain policies and procedures with respect to PHI that is used or disclosed, including the adoption of administrative, physical and

technical safeguards to protect such information.

If our relationship with Doctegrity and/or Doctegrity’s

relationship with its contracted physicians needed to be restructured in light of any such adverse changes or interpretations, that restructuring

could negatively affect our ability to connect consumers with medical providers in certain states, and thus those customers’ ability

to ultimately receive our products.

We do not have a

pharmacy and depend on a related party to compound our Mango product and other potential future men’s wellness products.(*)

We rely on a related party pharmacy

for the manufacture of our Mango product and will rely on this pharmacy or others for any potential future men’s wellness products

we market and we cannot assure you that they will be successful.

This subjects us to a number of risks, including the following:

we may not be able to control the commercialization of our products, including the amount, timing and quality of resources that our contracting parties may devote to our products;

our contracting parties may experience financial, regulatory or operational difficulties, which may impair their ability to fulfill their contractual obligations;

business combinations or significant changes in a contracting parties’ business strategy may adversely affect a contracting party’s willingness or ability to perform their obligations under any arrangement;

legal disputes or disagreements may occur with one or more of our contracting parties or between our contracting parties and our suppliers or former contracting parties;

a contracting party could independently move forward with a competing product developed either independently or in collaboration with others, including with one of our competitors.

If any of our contracting parties

fail to fulfill their future contractual obligations, our business may be negatively affected and we may receive limited or no revenues

under our agreements with them.

See also the risk factor, “ The related party pharmacy we have entered into an agreement with

may not receive licenses in all of the 50 United States to provide national coverage for us to sell our Mango ED product and future products ”

Our use and disclosure of

personally identifiable information, including health information, is subject to federal and state privacy and security regulations, and

our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or

reputational harm and, in turn, a material adverse effect on our client base and revenue.

Numerous state and federal laws

and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability and integrity of personally

identifiable information, or PII, including protected health information, or PHI.

These laws and regulations include the Health Information

Portability and Accountability Act of 1996 (“HIPAA”), as amended by the Health Information Technology for Economic and Clinical

Health Act, or HITECH, and their implementing regulations (referred to collectively as “HIPAA”).

HIPAA establishes a set of

basic national privacy and security standards for the protection of PHI.

HIPAA requires us to develop and maintain policies and procedures

with respect to PHI that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect

such information.

HIPAA imposes mandatory penalties for certain violations.

Penalties for violations

of HIPAA and its implementing regulations start at $100 per violation and are not to exceed $50,000 per violation, subject to a cap of

$1.5 million for violations of the same standard in a single calendar year.

However, a single breach incident can result in violations

of multiple standards.

HIPAA also authorizes state attorneys general to file suit on behalf of their residents.

Courts are able to award

damages, costs and attorneys’ fees related to violations of HIPAA in such cases.

While HIPAA does not create a private right of

action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care

in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.

In addition, HIPAA mandates that the

Secretary of Health and Human Services, or HHS, conduct periodic compliance audits of HIPAA covered entities or business associates for

compliance with the HIPAA Privacy and Security Standards.

It also tasks HHS with establishing a methodology whereby harmed individuals

who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator.

further requires that patients be notified of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises

the privacy or security of such information, with certain exceptions related to unintentional or inadvertent use or disclosure by employees

or authorized individuals.

HIPAA specifies that such notifications must be made “without unreasonable delay and in no case later

than 60 calendar days after discovery of the breach.” If a breach affects 500 patients or more, it must be reported to HHS without

unreasonable delay, and HHS will post the name of the breaching entity on its public web site.

Breaches affecting 500 patients or more

in the same state or jurisdiction must also be reported to the local media.

If a breach involves fewer than 500 people, the covered entity

must record it in a log and notify HHS at least annually.

other federal and state laws protect the confidentiality, privacy, availability, integrity and security of PII, including PHI.

laws in many cases are more restrictive than, and may not be pre-empted by, the HIPAA rules and may be subject to varying interpretations

by courts and government agencies, creating complex compliance issues for us and our clients and potentially exposing us to additional

expense, adverse publicity and liability.

of the extreme sensitivity of the PII we store and transmit, the security features of our technology platform are very important.

our security measures are breached or fail, unauthorized persons may be able to obtain access to sensitive client data, including HIPAA-regulated

As a result, our reputation could be severely damaged, adversely affecting client confidence.

In addition, we could face litigation,

damages for contract breach, penalties and regulatory actions for violation of HIPAA and other applicable laws or regulations and significant

costs for remediation, notification to individuals and for measures to prevent future occurrences.

Any potential security breach could

also result in increased costs associated with liability for stolen assets or information, repairing system damage that may have been

caused by such breaches, incentives offered to clients in an effort to maintain our business relationships after a breach and implementing

measures to prevent future occurrences, including organizational changes, deploying additional personnel and protection technologies,

training employees and engaging third-party experts and consultants.

Related to Related Party Relationships and Transactions and Our Management

depend heavily on our senior management, including our Chief Executive Officer, who may have a conflict of interest.

The ability of certain

key employees to devote adequate time to us is critical to the success of our business, and failure to do so may adversely affect our

revenues and as a result could materially adversely affect our business, financial condition and results of operations.(*)

must retain the services of our key employees and strategically recruit and hire new talented employees.

Our future business and results

of operations depend in significant part upon the continued contributions of our senior management personnel, particularly our Chairman

and Chief Executive Officer, Jacob D.

Cohen currently serves as a member of the Board of Directors of American International

Holdings Corp., as a co- Manager and 51% owner of Epiq Scripts, and as Chief Executive Officer of Ronin Equity Partners, Inc., a private

investment company, and in various positions with other entities and groups.

Cohen currently spends approximately 75% of his time

on Company matters.

Penalties for violations of HIPAA and its implementing regulations

start at $100 per violation and are not to exceed $50,000 per violation, subject to a cap of $1.5 million for violations of the same standard

in a single calendar year.

However, a single breach incident can result in violations of multiple standards.

HIPAA also authorizes state

attorneys general to file suit on behalf of their residents.

Courts are able to award damages, costs and attorneys’ fees related

to violations of HIPAA in such cases.

While HIPAA does not create a private right of action allowing individuals to sue us in civil court

for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence

or recklessness in the misuse or breach of PHI.

In addition, HIPAA mandates that the Secretary of Health and Human Services, or HHS, conduct

periodic compliance audits of HIPAA covered entities or business associates for compliance with the HIPAA Privacy and Security Standards.

It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive

a percentage of the Civil Monetary Penalty fine paid by the violator.

HIPAA further requires that patients be notified of any unauthorized

acquisition, access, use or disclosure of their unsecured PHI that compromises the privacy or security of such information, with certain

exceptions related to unintentional or inadvertent use or disclosure by employees or authorized individuals.

HIPAA specifies that such

notifications must be made “without unreasonable delay and in no case later than 60 calendar days after discovery of the breach.”

If a breach affects 500 patients or more, it must be reported to HHS without unreasonable delay, and HHS will post the name of the breaching

entity on its public web site.

Breaches affecting 500 patients or more in the same state or jurisdiction must also be reported to the

If a breach involves fewer than 500 people, the covered entity must record it in a log and notify HHS at least annually.

Numerous other federal and state

laws protect the confidentiality, privacy, availability, integrity and security of PII, including PHI.

These laws in many cases are more

restrictive than, and may not be pre-empted by, the HIPAA rules and may be subject to varying interpretations by courts and government

agencies, creating complex compliance issues for us and our clients and potentially exposing us to additional expense, adverse publicity

and liability.

Because of the extreme sensitivity

of the PII we store and transmit, the security features of our technology platform are very important.

If our security measures are breached

or fail, unauthorized persons may be able to obtain access to sensitive client data, including HIPAA-regulated PHI.

As a result, our reputation

could be severely damaged, adversely affecting client confidence.

In addition, we could face litigation, damages for contract breach,

penalties and regulatory actions for violation of HIPAA and other applicable laws or regulations and significant costs for remediation,

notification to individuals and for measures to prevent future occurrences.

Any potential security breach could also result in increased

costs associated with liability for stolen assets or information, repairing system damage that may have been caused by such breaches,

incentives offered to clients in an effort to maintain our business relationships after a breach and implementing measures to prevent

future occurrences, including organizational changes, deploying additional personnel and protection technologies, training employees and

engaging third-party experts and consultants.

Risks Related to Related Party Relationships and

Transactions and Our Management

We depend heavily on our

senior management, including our Chief Executive Officer, who may have a conflict of interest.

The ability of certain key employees to

devote adequate time to us is critical to the success of our business, and failure to do so may adversely affect our revenues and as a

result could materially adversely affect our business, financial condition and results of operations.(*)

We must retain the services of

our key employees and strategically recruit and hire new talented employees.

Our future business and results of operations depend in significant

part upon the continued contributions of our senior management personnel, particularly our Chairman and Chief Executive Officer, Jacob

Cohen currently serves as a member of the Board of Directors of American International Holdings Corp., as a co- Manager

and 51% owner of Epiq Scripts, and as Chief Executive Officer of Ronin Equity Partners, Inc., a private investment company, and in various

positions with other entities and groups.

Cohen currently spends approximately 75% of his time on Company matters.

As a result, Mr.

Cohen dedicates only a portion of his professional efforts to our business and operations, and there

is no contractual obligation for him to spend a specific amount of his time with us.

Cohen may not be able to dedicate adequate time

to our business and operations and we could experience an adverse effect on our operations due to the demands placed on him from his

other professional obligations.

Such involvement in other businesses may therefore present a conflict of interest regarding decisions

he makes for us or with respect to the amount of time available for us.

If we lose his services or if he fails to perform in his current

position, or if we are not able to attract and retain skilled personnel as needed, our business could suffer.

Significant turnover in

our senior management could significantly deplete our institutional knowledge held by our existing senior management team.

on the skills and abilities of these key personnel in managing our operations, product development, marketing and sales aspects of our

business, any part of which could be harmed by turnover in the future.

forward, should the services of Mr.

Cohen be lost for any reason, we will incur costs associated with recruiting replacements and any

potential delays in operations which this may cause.

If we are unable to replace such individual with a suitably trained alternative

individual(s), we may be forced to scale back or curtail our business plan.

if our executive officers do not devote sufficient time towards our business, we may never be able to effectuate our business plan.

have engaged and in the future plan to engage in transactions with related parties and such transactions present possible conflicts of

interest that could have an adverse effect on us.

have entered, and may continue to enter, into transactions with related parties for financing, corporate, business development and operational

Included in such transactions is a Master Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party,

51% owned and controlled by Jacob D.

Cohen dedicates only a portion of his professional efforts to our business and operations, and there is no contractual obligation for

him to spend a specific amount of his time with us.

Cohen may not be able to dedicate adequate time to our business and operations

and we could experience an adverse effect on our operations due to the demands placed on him from his other professional obligations.

Such involvement in other businesses may therefore present a conflict of interest regarding decisions he makes for us or with respect

to the amount of time available for us.

If we lose his services or if he fails to perform in his current position, or if we are not able

to attract and retain skilled personnel as needed, our business could suffer.

Significant turnover in our senior management could significantly

deplete our institutional knowledge held by our existing senior management team.

We depend on the skills and abilities of these key personnel

in managing our operations, product development, marketing and sales aspects of our business, any part of which could be harmed by turnover

in the future.

Moving forward, should the services

Cohen be lost for any reason, we will incur costs associated with recruiting replacements and any potential delays in operations

which this may cause.

If we are unable to replace such individual with a suitably trained alternative individual(s), we may be forced

to scale back or curtail our business plan.

Separately, if our executive officers

do not devote sufficient time towards our business, we may never be able to effectuate our business plan.

We have engaged and in the

future plan to engage in transactions with related parties and such transactions present possible conflicts of interest that could have

an adverse effect on us.

We have entered, and may continue

to enter, into transactions with related parties for financing, corporate, business development and operational services.

such transactions is a Master Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party, 51% owned and controlled

Cohen, our Chairman and Chief Executive Officer, for pharmacy and compounding services.

Such transactions

may not have been/may not be, entered into on an arm’s-length basis, and we may have achieved more or less favorable terms because

such transactions were entered into with our related parties.

This could have a material effect on our business, results of operations

and financial condition.

Such conflicts could cause an individual in our management to seek to advance his or her economic interests

or the economic interests of certain related parties above ours.

Further, the appearance of conflicts of interest created by related

party transactions could impair the confidence of our investors.

expect to be significantly reliant on related party relationships.(*)

have entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party, 51% owned and controlled

Cohen, our Chairman and Chief Executive Officer, who also serves as a co-Manager of Epiq Scripts, for pharmacy and compounding

In the event that relationship is terminated, our costs may increase, and we may be unable to effectively obtain the services

currently provided by Epiq Scripts, LLC.

Such transactions may not have been/may

not be, entered into on an arm’s-length basis, and we may have achieved more or less favorable terms because such transactions were

entered into with our related parties.

This could have a material effect on our business, results of operations and financial condition.

Such conflicts could cause an individual in our management to seek to advance his or her economic interests or the economic interests

of certain related parties above ours.

Further, the appearance of conflicts of interest created by related party transactions could impair

the confidence of our investors.

We are significantly

reliant on related party relationships.(*)

We have entered into a Master

Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party, 51% owned and controlled by Jacob D.

Cohen, our Chairman

and Chief Executive Officer, who also serves as a co-Manager of Epiq Scripts, for pharmacy and compounding services.

In the event that

relationship is terminated, our costs may increase, and we may be unable to effectively obtain the services currently provided by Epiq

Scripts, LLC.

Additionally, certain of our consultants are employed by Epiq Scripts, LLC.

We also anticipate

entering into other related party relationships in the future.

While we believe that all related party agreements have been and will

be on arms-length terms, such significant related party relationships may be perceived negatively by potential shareholders or investors

and/or may result in conflicts of interest.

Each of our officers and directors (including those discussed above) presently has, and any

of them in the future may have, additional fiduciary or contractual obligations to other entities pursuant to which such officer or director

may be required to present a business opportunity to such entity, subject to his or her fiduciary duties under applicable law.

Additionally,

such persons may have conflicts of interest in allocating their time among various business activities.

These conflicts may not be resolved

in our favor.

Our significant related party relationships and transactions, the terms of such relationships and transactions, and/or

the termination of any such relationships or transactions, may have a material adverse effect on our results of operations moving forward

and/or create conflicts of interest or perceived conflicts of interest which may have a material adverse effect on the value of our securities.

related party pharmacy we have entered into an agreement with may not receive licenses in all of the 50 United States to provide national

coverage for us to sell our Mango ED product and future products.(*)

have entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party, 51% owned and controlled

Cohen, our Chairman and Chief Executive Officer, for pharmacy and compounding services.

Epiq Script’s ability to provide

pharmacy services in each state is subject to among other things, receipt of regulatory approvals and licenses in the states in which

we plan to operate.

Currently Epiq Scripts holds State Board of Pharmacy (or its equivalent) licenses to operate in 44 states:

Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Maine, Maryland,

Massachusetts, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina,

North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington,

West Virginia, Wisconsin, and Wyoming..

Its failure to receive regulatory approval or licenses in the other states in which we hope to

operate, or loss of such licenses in the future, may prohibit us from selling our Mango products to customers that reside in those states

limiting our ability to grow and compete with other companies that have those capabilities.

Any of the above may have an adverse effect

on our revenues, operations and cash flow and cause the value of our securities to decline in value or become worthless.

related party conflicts associated with our engagement of Epiq Scripts, LLC as discussed in greater detail above.

Cohen, our Chairman and Chief Executive Officer, beneficially owns greater than 50% of our outstanding common stock and exercises

majority voting control over us, which will limit shareholders’ abilities to influence corporate matters and could delay or prevent

a change in corporate control.(*)

Cohen beneficially owns approximately 51.7% of the issued and outstanding shares of our common stock.

As a result, he controls the shareholder

Consequently, he has the ability to influence matters affecting our shareholders and therefore exercises control in determining

the outcome of all corporate transactions or other matters, including (i) making amendments to our certificate of formation;

to issue additional shares of common stock and preferred stock, including to himself;

(iii) employment decisions, including compensation

arrangements;

(iv) whether to enter into material transactions with related parties;

We also anticipate entering into other related

party relationships in the future.

While we believe that all related party agreements have been and will be on arms-length terms, such

significant related party relationships may be perceived negatively by potential shareholders or investors and/or may result in conflicts

Each of our officers and directors (including those discussed above) presently has, and any of them in the future may have,

additional fiduciary or contractual obligations to other entities pursuant to which such officer or director may be required to present

a business opportunity to such entity, subject to his or her fiduciary duties under applicable law.

Additionally, such persons may have

conflicts of interest in allocating their time among various business activities.

These conflicts may not be resolved in our favor.

significant related party relationships and transactions, the terms of such relationships and transactions, and/or the termination of

any such relationships or transactions, may have a material adverse effect on our results of operations moving forward and/or create conflicts

of interest or perceived conflicts of interest which may have a material adverse effect on the value of our securities.

The related party pharmacy

we have entered into an agreement with may not receive licenses in all of the 50 United States to provide national coverage for us to

sell our Mango ED product and future products.(*)

We have entered into a

Master Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party, 51% owned and controlled by Jacob D.

our Chairman and Chief Executive Officer, for pharmacy and compounding services.

Epiq Script’s ability to provide pharmacy

services in each state is subject to among other things, receipt of regulatory approvals and licenses in the states in which we plan

Currently Epiq Scripts holds State Board of Pharmacy (or its equivalent) licenses to operate in the District of Columbia

and 45 states:

Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho,

Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska,

Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode

Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.

Its failure to

receive regulatory approval or licenses in the other states in which we hope to operate, or loss of such licenses in the future, may

prohibit us from selling our Mango products to customers that reside in those states limiting our ability to grow and compete with

other companies that have those capabilities.

Any of the above may have an adverse effect on our revenues, operations and cash flow

and cause the value of our securities to decline in value or become worthless.

We also face related party conflicts associated with

our engagement of Epiq Scripts, LLC as discussed in greater detail above.

Chairman and Chief Executive Officer and Jonathan Arango, our President, Chief Operating Officer and Director, beneficially own greater than 50% of our outstanding common stock and exercises majority

voting control over us, which will limit shareholders’ abilities to influence corporate matters and could delay or prevent a

change in corporate control.(*)

Cohen, our Chairman

and Chief Executive Officer and Jonathan Arango, our President, Chief Operating Officer and Director beneficially owns approximately

54.7% of the issued and outstanding shares of our common stock.

As a result, they control the shareholder vote.

Consequently, they have

the ability to influence matters affecting our shareholders and therefore exercises control in determining the outcome of all corporate

transactions or other matters, including (i) making amendments to our certificate of formation;

(ii) whether to issue additional shares

of common stock and preferred stock, including to himself;

(iii) employment decisions, including compensation arrangements;

to enter into material transactions with related parties;

(v) election of directors;

and (vi) any merger or

significant corporate transactions, including with himself or other related parties.

Additionally, it will be difficult if not impossible

for investors to remove our current directors, which will mean they will remain in control of who serves as officers of the Company as

well as whether any changes are made in the Board of Directors.

As a potential investor in the Company, you should keep in mind that

even if you own shares of our common stock and wish to vote them at annual or special shareholder meetings, your shares will likely have

little effect on the outcome of corporate decisions.

Cohen controls the vote on all shareholder matters, investors may find

it difficult to replace our management if they disagree with the way our business is being operated.

The interests of Mr.

Cohen may not

coincide with our interests or the interests of other shareholders.

Cohen acquired his shares of common stock for substantially less than the price of the shares of common stock acquired in our IPO and/or

the current trading price of our common stock, and may have interests, with respect to his common stock, that are different from other

investors and the concentration of voting power held by Mr.

Cohen may have an adverse effect on the price of our common stock.

addition, this concentration of ownership might adversely affect the market price of our common stock by:

(1) delaying, deferring or

preventing a change of control of our Company;

(2) impeding a merger, consolidation, takeover or other business combination involving

or (3) discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our Company.

Cohen, our Chairman and Chief Executive Officer, beneficially owns greater than 50% of our outstanding shares of common stock, which

causes us to be deemed a “controlled company” under the rules of Nasdaq.

Cohen currently controls approximately 51.7% of the voting power of our capital stock.

As such, we are a “controlled company”

under the rules of Nasdaq.

Under these rules, a company of which more than 50% of the voting power is held by an individual, a group

or another company is a “controlled company” and can elect to be exempt from certain corporate governance requirements, including

requirements that:

of the Board of Directors consist of independent directors;

the board maintain

a nominations committee with prescribed duties and a written charter;

the board maintain a Compensation

Committee with prescribed duties and a written charter and comprised solely of independent directors.

a “controlled company,” we may elect to rely on some or all of these exemptions, although we do not currently intend to take

advantage of any of these exemptions.

Accordingly, should the interests of Mr.

Cohen differ from those of other shareholders, and/or

we choose to take advantage of the “controlled company” exemptions, other shareholders may not have the same protections

afforded to shareholders of companies that are subject to all of the Nasdaq corporate governance standards.

Even if we do not avail ourselves

of these exemptions in the future, our status as a controlled company could make our common stock less attractive to some investors or

otherwise harm our stock price.

If we choose to take advantage of the exemptions under the rules of Nasdaq relating to “controlled

companies” in the future, you will not have the same protections afforded to shareholders of companies that are subject to all

of the corporate governance requirements of Nasdaq.

competition from our existing executive officers, after they leave their employment with us, and subject to the non-compete terms of

their employment agreements, could negatively impact our profitability.(*)

our Chief Executive Officer, Jacob D.

Cohen, our President, Jonathan Arango, and our Chief Operating Officer, Amanda Hammer, are prohibited

from competing with us while they are employed with us and for 12 months thereafter (subject to the terms of, and exceptions set forth

in, their employment agreements with the Company), none of such individuals will be prohibited from competing with us after such 12-month

Accordingly, any of these individuals could be in a position to use industry experience gained while working with us to

compete with us.

Such competition could distract or confuse customers, reduce the value of our intellectual property and trade secrets,

or reduce our future revenues, earnings or growth prospects.

Related to Intellectual Property

operate in an industry with the risk of intellectual property litigation.

and (vi) any merger or significant corporate transactions,

including with himself or other related parties.

Additionally, it will be difficult if not impossible for investors to remove our current

directors (including, but not limited to Mr.

Cohen and Mr.

Arango), which will mean they will remain in control of who serves as officers

of the Company as well as whether any changes are made in the Board of Directors.

As a potential investor in the Company, you should

keep in mind that even if you own shares of our common stock and wish to vote them at annual or special shareholder meetings, your shares

will likely have little effect on the outcome of corporate decisions.

Cohen and Mr.

Arango control the vote on all shareholder

matters, investors may find it difficult to replace our management if they disagree with the way our business is being operated.

interests of Mr.

Cohen and Mr.

Arango may not coincide with our interests or the interests of other shareholders.

Cohen and Mr.

acquired their shares of common stock for substantially less than the price of the shares of common stock acquired in our IPO and/or

the current trading price of our common stock, and may have interests, with respect to their common stock, that are different from

other investors and the concentration of voting power held by Mr.

Cohen and Mr.

Arango may have an adverse effect on the price of

our common stock.

In addition, this concentration

of ownership might adversely affect the market price of our common stock by:

(1) delaying, deferring or preventing a change of control

of our Company;

(2) impeding a merger, consolidation, takeover or other business combination involving our Company;

or (3) discouraging

a potential acquirer from making a tender offer or otherwise attempting to obtain control of our Company.

Potential competition from

our existing executive officers, after they leave their employment with us, and subject to the non-compete terms of their employment agreements,

could negatively impact our profitability.(*)

Although our Chief Executive Officer,

Cohen, our President, Jonathan Arango, and our Chief Operating Officer, Amanda Hammer, are prohibited from competing with us

while they are employed with us and for 12 months thereafter (subject to the terms of, and exceptions set forth in, their employment agreements

with the Company), none of such individuals will be prohibited from competing with us after such 12-month period ends.

Accordingly, any

of these individuals could be in a position to use industry experience gained while working with us to compete with us.

Such competition

could distract or confuse customers, reduce the value of our intellectual property and trade secrets, or reduce our future revenues, earnings

or growth prospects.

Risks Related to Intellectual Property

We operate in an industry

with the risk of intellectual property litigation.

Claims of infringement against us may hurt our business.

must protect the proprietary nature of the intellectual property used in our business.

There can be no assurance that trade secrets and

other intellectual property will not be challenged, invalidated, misappropriated or circumvented by third parties.

Additionally,

our success depends, in part, upon non-infringement of intellectual property rights owned by others and being able to resolve claims

of intellectual property infringement without major financial expenditures or adverse consequences.

Participants that own, or claim to

own, intellectual property may aggressively assert their rights.

From time to time, we may be subject to legal proceedings and claims

relating to the intellectual property rights of others.

Future litigation may be necessary to defend us by determining the scope, enforceability,

and validity of third-party proprietary rights or to establish its proprietary rights.

Our competitors have substantially greater resources

and are able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time.

addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.

Regardless of whether claims that we are infringing patents or other intellectual property rights have any merit, these claims are time-consuming

and costly to evaluate and defend and could:

or stoppages in providing products;

divert management’s

attention and resources;

require technology changes

to our products that would cause our Company to incur substantial cost;

subject us to significant

require us to cease some

or all of our activities.

addition to liability for monetary damages, which may be tripled and may include attorneys’ fees, or, in some circumstances, damages

against clients, we may be prohibited from developing, commercializing, or continuing to provide some or all of our products unless we

obtain licenses from, and pay royalties to, the holders of the patents or other intellectual property rights, which may not be available

on commercially favorable terms, or at all.

Related to the Telehealth Operations of Our Contracting Parties

telehealth business of our telehealth provider could be adversely affected by ongoing legal challenges or by new state actions restricting

the ability to provide telehealth services in certain states.

business plan contemplates the use of telehealth providers to provide telehealth consultations and related services on our Mangoceuticals

platform, which connects users/customers with third-party health care providers and Epiq Scripts, LLC, a related party pharmacy.

entered into an agreement with Doctegrity, pursuant to which Doctegrity has agreed to provide clinical services directly to our customers

via telehealth.

Through these arrangements, the professionals or professional entities are responsible for the practice of medicine and

control of the clinical decision-making.

ability to conduct business operations in each state is dependent upon the state’s treatment of medicine under such state’s

laws, and rules and policies governing the practice of physician supervised services, which are subject to changing political, regulatory

We must protect the proprietary

nature of the intellectual property used in our business.

There can be no assurance that trade secrets and other intellectual property

will not be challenged, invalidated, misappropriated or circumvented by third parties.

Additionally, our success depends,

in part, upon non-infringement of intellectual property rights owned by others and being able to resolve claims of intellectual property

infringement without major financial expenditures or adverse consequences.

Participants that own, or claim to own, intellectual property

may aggressively assert their rights.

From time to time, we may be subject to legal proceedings and claims relating to the intellectual

property rights of others.

Future litigation may be necessary to defend us by determining the scope, enforceability, and validity of third-party

proprietary rights or to establish its proprietary rights.

Our competitors have substantially greater resources and are able to sustain

the costs of complex intellectual property litigation to a greater degree and for longer periods of time.

In addition, patent holding

companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.

Regardless of whether claims

that we are infringing patents or other intellectual property rights have any merit, these claims are time-consuming and costly to evaluate

and defend and could:

cause delays or stoppages in providing products;

divert management’s attention and resources;

require technology changes to our products that would cause our Company to incur substantial cost;

subject us to significant liabilities;

require us to cease some or all of our activities.

In addition to liability for monetary

damages, which may be tripled and may include attorneys’ fees, or, in some circumstances, damages against clients, we may be prohibited

from developing, commercializing, or continuing to provide some or all of our products unless we obtain licenses from, and pay royalties

to, the holders of the patents or other intellectual property rights, which may not be available on commercially favorable terms, or at

Risks Related to the Telehealth Operations of Our

Contracting Parties

The telehealth business

of our telehealth provider could be adversely affected by ongoing legal challenges or by new state actions restricting the ability to

provide telehealth services in certain states.

We use telehealth providers to provide telehealth consultations and related services on our Mangoceuticals platform, which connects

users/customers with third-party health care providers and Epiq Scripts, LLC, a related party pharmacy.

We have entered into an agreement

with Doctegrity, pursuant to which Doctegrity provides clinical services directly to our customers via telehealth.

these arrangements, the professionals or professional entities are responsible for the practice of medicine and control of the clinical

decision-making.

Our ability to conduct business

operations in each state is dependent upon the state’s treatment of medicine under such state’s laws, and rules and policies

governing the practice of physician supervised services, which are subject to changing political, regulatory and other influences.

We depend on our contracted parties

to maintain appropriate telehealth licenses to be able to provide telehealth services to our potential customers and prescribe them our

products, which are required to be prescribed by licensed physicians.

In the event we are not able to maintain relationships with telehealth

providers, state licensing laws make it harder, more costly or impossible to provide telehealth services, or our customers are otherwise

unable to obtain prescriptions for our products, we may be unable to sell products, which could result in us having to curtail our business

plan or cease operating.

Our contracting parties’

telehealth business could be adversely affected by ongoing legal challenges to their business model or by new state actions restricting

their ability to provide the full range of services in certain states.

The ability of our contracted

parties’ telehealth operations in each state is dependent upon the state’s treatment of medicine under such state’s

laws, rules and policies governing the practice of physician supervised services, which are subject to changing political, regulatory

and other influences.

depend on our contracted parties to maintain appropriate telehealth licenses to be able to provide telehealth services to our potential

customers and prescribe them our products, which are required to be prescribed by licensed physicians.

In the event we are not able to

maintain relationships with telehealth providers, state licensing laws make it harder, more costly or impossible to provide telehealth

services, or our customers are otherwise unable to obtain prescriptions for our products, we may be unable to sell products, which could

result in us having to curtail our business plan or cease operating.

contracting parties’ telehealth business could be adversely affected by ongoing legal challenges to their business model or by

new state actions restricting their ability to provide the full range of services in certain states.

ability of our contracted parties’ telehealth operations in each state is dependent upon the state’s treatment of medicine

under such state’s laws, rules and policies governing the practice of physician supervised services, which are subject to changing

political, regulatory and other influences.

In the event our contracted parties are unable to provide telehealth services for any reason,

it would have a material adverse effect on our ability to sell products and in turn our revenues and operating results.

Related to Our Governing Documents and Texas Law

Certificate of Formation, Bylaws and Texas law provide for indemnification of officers and directors at our expense and limit the liability

of our directors, which may result in a major cost to us and hurt the interests of our shareholders because corporate resources may be

expended for the benefit of officers or directors.

Certificate of Formation, Bylaws and Texas law provide for us to indemnify and hold harmless, to the fullest extent permitted by applicable

law, each person who is or was made a party or is threatened to be made a party to or is otherwise involved in any threatened, pending

or completed action, suit or proceeding by reason of the fact that he or she is or was a director or officer of the Company or, while

a director or officer of the Company, is or was serving at the request of the Company as a director, officer, employee or agent of another

corporation or of a partnership, joint venture, trust, other enterprise or nonprofit entity, including service with respect to an employee

benefit plan.

Our Certificate of Formation also provides that the personal liability of our directors is eliminated to the fullest extent

permitted by the Texas Business Organizations Code, as such may be amended or supplemented.

These indemnification obligations and limitations

of liability may result in a major cost to us and hurt the interests of our shareholders because corporate resources may be expended

for the benefit of officers or directors.

have been advised that, in the opinion of the SEC, indemnification for liabilities arising under federal securities laws is against public

policy as expressed in the Securities Act and is, therefore, unenforceable.

In the event that a claim for indemnification for liabilities

arising under federal securities laws, other than the payment by us of expenses incurred or paid by a director, officer or controlling

person in the successful defense of any action, suit or proceeding, is asserted by a director, officer or controlling person in connection

with our activities, we will (unless in the opinion of our counsel, the matter has been settled by controlling precedent) submit to a

court of appropriate jurisdiction, the question whether indemnification by us is against public policy as expressed in the Securities

Act and will be governed by the final adjudication of such issue.

The legal process relating to this matter if it were to occur is likely

to be very costly and may result in us receiving negative publicity, either of which factors is likely to materially reduce the market

and price for our shares.

have established preferred stock which can be designated by our Board of Directors without shareholder approval.

have 10,000,000 shares of preferred stock authorized.

The shares of our preferred stock may be issued from time to time in one or more

series, each of which shall have a distinctive designation or title as shall be determined by our Board of Directors prior to the issuance

of any shares thereof.

The preferred stock shall have such voting powers, full or limited, or no voting powers, and such preferences

and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof as adopted

by the Board of Directors.

Because the Board of Directors is able to designate the powers and preferences of the preferred stock without

the vote of a majority of our shareholders, our shareholders will have no control over what designations and preferences our preferred

stock will have.

The issuance of shares of preferred stock or the rights associated therewith, could cause substantial dilution to our

existing shareholders.

Additionally, the dilutive effect of any preferred stock which we may issue may be exacerbated given the fact

that such preferred stock may have voting rights and/or other rights or preferences which could provide the preferred shareholders with

substantial voting control over us and/or give those holders the power to prevent or cause a change in control, even if that change in

control might benefit our shareholders.

As a result, the issuance of shares of preferred stock may cause the value of our securities

Anti-takeover

provisions in our Certificate of Formation and our Bylaws, as well as provisions of Texas law, might discourage, delay or prevent a change

in control of our company or changes in our management and, therefore, depress the trading price of our common stock.

Certificate of Formation, Bylaws and Texas law contain provisions that may discourage, delay or prevent a merger, acquisition or other

change in control that shareholders may consider favorable, including transactions in which you might otherwise receive a premium for

your shares of our common stock.

These provisions may also prevent or delay attempts by our shareholders to replace or remove our management.

Our corporate governance documents include provisions:

requiring advance

notice of shareholder proposals for business to be conducted at meetings of our shareholders and for nominations of candidates for

election to our Board of Directors;

authorizing blank check

preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common stock;

providing indemnification

to, our directors and officers.

existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the

future for shares of our common stock.

They could also deter potential acquirers of our company, thereby reducing the likelihood that

you could receive a premium for your common stock in an acquisition.

In the event our contracted parties are unable to provide telehealth services for any reason, it would have a material

adverse effect on our ability to sell products and in turn our revenues and operating results.

Risks Related to Our Governing Documents and Texas

Our Certificate of Formation,

Bylaws and Texas law provide for indemnification of officers and directors at our expense and limit the liability of our directors, which

may result in a major cost to us and hurt the interests of our shareholders because corporate resources may be expended for the benefit

of officers or directors.

Our Certificate of Formation,

Bylaws and Texas law provide for us to indemnify and hold harmless, to the fullest extent permitted by applicable law, each person who

is or was made a party or is threatened to be made a party to or is otherwise involved in any threatened, pending or completed action,

suit or proceeding by reason of the fact that he or she is or was a director or officer of the Company or, while a director or officer

of the Company, is or was serving at the request of the Company as a director, officer, employee or agent of another corporation or of

a partnership, joint venture, trust, other enterprise or nonprofit entity, including service with respect to an employee benefit plan.

Our Certificate of Formation also provides that the personal liability of our directors is eliminated to the fullest extent permitted

by the Texas Business Organizations Code, as such may be amended or supplemented.

These indemnification obligations and limitations of

liability may result in a major cost to us and hurt the interests of our shareholders because corporate resources may be expended for

the benefit of officers or directors.

We have been advised that, in

the opinion of the SEC, indemnification for liabilities arising under federal securities laws is against public policy as expressed in

the Securities Act and is, therefore, unenforceable.

In the event that a claim for indemnification for liabilities arising under federal

securities laws, other than the payment by us of expenses incurred or paid by a director, officer or controlling person in the successful

defense of any action, suit or proceeding, is asserted by a director, officer or controlling person in connection with our activities,

we will (unless in the opinion of our counsel, the matter has been settled by controlling precedent) submit to a court of appropriate

jurisdiction, the question whether indemnification by us is against public policy as expressed in the Securities Act and will be governed

by the final adjudication of such issue.

The legal process relating to this matter if it were to occur is likely to be very costly and

may result in us receiving negative publicity, either of which factors is likely to materially reduce the market and price for our shares.

We have established preferred

stock which can be designated by our Board of Directors without shareholder approval.

We have 10,000,000 shares of preferred

stock authorized.

The shares of our preferred stock may be issued from time to time in one or more series, each of which shall have a

distinctive designation or title as shall be determined by our Board of Directors prior to the issuance of any shares thereof.

The preferred

stock shall have such voting powers, full or limited, or no voting powers, and such preferences and relative, participating, optional

or other special rights and such qualifications, limitations or restrictions thereof as adopted by the Board of Directors.

Board of Directors is able to designate the powers and preferences of the preferred stock without the vote of a majority of our shareholders,

our shareholders will have no control over what designations and preferences our preferred stock will have.

The issuance of shares of

preferred stock or the rights associated therewith, could cause substantial dilution to our existing shareholders.

Additionally, the dilutive

effect of any preferred stock which we may issue may be exacerbated given the fact that such preferred stock may have voting rights and/or

other rights or preferences which could provide the preferred shareholders with substantial voting control over us and/or give those holders

the power to prevent or cause a change in control, even if that change in control might benefit our shareholders.

As a result, the issuance

of shares of preferred stock may cause the value of our securities to decrease.

Anti-takeover provisions

in our Certificate of Formation and our Bylaws, as well as provisions of Texas law, might discourage, delay or prevent a change in control

of our company or changes in our management and, therefore, depress the trading price of our common stock.

Our Certificate of Formation,

Bylaws and Texas law contain provisions that may discourage, delay or prevent a merger, acquisition or other change in control that shareholders

may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock.

provisions may also prevent or delay attempts by our shareholders to replace or remove our management.

Our corporate governance documents

include provisions:

requiring advance notice of shareholder proposals for business to be conducted at meetings of our shareholders and for nominations of candidates for election to our Board of Directors;

authorizing blank check preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common stock;

providing indemnification to, our directors and officers.

The existence of the foregoing

provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares

of our common stock.

They could also deter potential acquirers of our company, thereby reducing the likelihood that you could receive

a premium for your common stock in an acquisition.

Related to Our Securities

recent initial public offerings of companies with public floats comparable to the anticipated public float of the Company have experienced

extreme volatility that was seemingly unrelated to the underlying performance of the respective company.

We have in the past, and may

in the future experience similar volatility, which may make it difficult for prospective investors to assess the value of our common

addition to the risks addressed below under the heading “— Our common stock prices have been, and may continue to be,

volatile and could decline substantially ,” our common stock may be subject to extreme volatility that is seemingly unrelated

to the underlying performance of our business.

For example, since our common stock began trading on the Nasdaq Capital Market in connection

with our IPO on March 20, 2023, the trading price of our common stock has traded as high as $4.37 and as low as $0.86 per share.

trading price of our common stock is expected to continue to be volatile, and our common stock may be subject to rapid and substantial

price volatility.

Such volatility, including any stock-run up, may be unrelated to our actual or expected operating performance, financial

condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our common stock.

have been recent instances of extreme stock price run-ups followed by rapid price declines following initial public offerings, particularly

among companies with relatively smaller public floats, and we expect that such instances may continue and/or increase in the future.

may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of additional shares

of our common stock.(+)

possible, our Board of Directors will attempt to use non-cash consideration to satisfy obligations.

In many instances, we believe that

the non-cash consideration will consist of restricted shares of our common stock or where shares are to be issued to our officers, directors

and applicable consultants.

Our Board of Directors has authority, without action or vote of the stockholders, but subject to Nasdaq rules

and regulations (which generally require stockholder approval for any transactions which would result in the issuance of more than 20%

of our then outstanding shares of common stock or voting rights representing over 20% of our then outstanding shares of stock), to issue

all or part of the authorized but unissued shares of common stock.

In addition, we may attempt to raise capital by selling shares of

our common stock, possibly at a discount to market.

These actions will result in dilution of the ownership interests of existing stockholders,

which may further dilute common stock book value, and that dilution may be material.

Such issuances may also serve to enhance existing

management’s ability to maintain control of the Company because the shares may be issued to parties or entities committed to supporting

existing management.

Certain recent initial public

offerings of companies with public floats comparable to the anticipated public float of the Company have experienced extreme volatility

that was seemingly unrelated to the underlying performance of the respective company.

We have in the past, and may in the future experience

similar volatility, which may make it difficult for prospective investors to assess the value of our common stock.(*)

In addition to the risks addressed

below under the heading “— Our common stock prices have been, and may continue to be, volatile and could decline substantially ,”

our common stock may be subject to extreme volatility that is seemingly unrelated to the underlying performance of our business.

since our common stock began trading on the Nasdaq Capital Market in connection with our IPO on March 20, 2023, the trading price of our

common stock has traded as high as $4.37 and as low as $0.86 per share.

The trading price of our common stock is expected to continue

to be volatile, and our common stock may be subject to rapid and substantial price volatility.

Such volatility, including any stock-run

up, may be unrelated to our actual or expected operating performance, financial condition or prospects, making it difficult for prospective

investors to assess the rapidly changing value of our common stock.

There have been recent instances of extreme stock price run-ups followed

by rapid price declines following initial public offerings, particularly among companies with relatively smaller public floats, and we

expect that such instances may continue and/or increase in the future.

Contributing to this risk of volatility are a number of factors.

First, our common stock is likely to be more sporadically and thinly

traded than that of larger, more established companies.

As a consequence of this lack of liquidity, the trading of relatively small quantities

of shares by our shareholders may disproportionately influence the price of those shares in either direction, which may cause our stock

price to deviate, potentially significantly, from a price that better reflects the underlying performance of our business.

of our shares could, for example, decline precipitously in the event that a large number of our shares are sold in the market without

commensurate demand (including as our IPO lockups expire – 12 months after the IPO (unless earlier waived in the discretion of

the underwriter of the IPO)) as compared to a seasoned issuer that could better absorb those sales without an adverse impact on its stock

Second, we are a speculative investment due to our limited operating history, not being profitable, and not expecting to be profitable

in the near term.

As a consequence of this enhanced risk, more risk-adverse investors may, under the fear of losing all or most of their

investment in the event of negative news or lack of progress, be more inclined to sell their shares on the market more quickly and at

greater discounts than would be the case with the stock of a larger, more established company that has a relatively large public float.

of these factors are beyond our control and may decrease the market price of our securities.

Such volatility, including any stock run-ups,

may be unrelated or disproportionate to our actual or expected operating performance and financial condition or prospects, making it

difficult for prospective investors to assess the rapidly changing value of our shares.

the stock market in general, and the market for men’s wellness product companies in particular, have experienced extreme price

and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies.

and industry factors, as well as general economic, political and market conditions such as recessions, or changes in inflation or interest

rates, may seriously affect the market price of our securities, regardless of our actual operating performance.

As a result of this volatility,

investors may experience losses on their investment in our common stock.

A decline in the market price of our common stock also could

adversely affect our ability to issue additional shares of common stock or other securities and our ability to obtain additional financing

in the future.

First, our common stock is likely to be more sporadically and thinly traded than that of larger, more established companies.

As a consequence

of this lack of liquidity, the trading of relatively small quantities of shares by our shareholders may disproportionately influence the

price of those shares in either direction, which may cause our stock price to deviate, potentially significantly, from a price that better

reflects the underlying performance of our business.

The price of our shares could, for example, decline precipitously in the event that

a large number of our shares are sold in the market without commensurate demand (including as our IPO lockups expire – 12 months

after the IPO (unless earlier waived in the discretion of the underwriter of the IPO)) as compared to a seasoned issuer that could better

absorb those sales without an adverse impact on its stock price.

Second, we are a speculative investment due to our limited operating

history, not being profitable, and not expecting to be profitable in the near term.

As a consequence of this enhanced risk, more risk-adverse

investors may, under the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined

to sell their shares on the market more quickly and at greater discounts than would be the case with the stock of a larger, more established

company that has a relatively large public float.

Many of these factors are beyond

our control and may decrease the market price of our securities.

Such volatility, including any stock run-ups, may be unrelated or disproportionate

to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to

assess the rapidly changing value of our shares.

Furthermore, the stock market

in general, and the market for men’s wellness product companies in particular, have experienced extreme price and volume fluctuations

that have often been unrelated or disproportionate to the operating performance of those companies.

Broad market and industry factors,

as well as general economic, political and market conditions such as recessions, or changes in inflation or interest rates, may seriously

affect the market price of our securities, regardless of our actual operating performance.

As a result of this volatility, investors may

experience losses on their investment in our common stock.

A decline in the market price of our common stock also could adversely affect

our ability to issue additional shares of common stock or other securities and our ability to obtain additional financing in the future.

No assurance can be given that an active market in our common shares will develop or be sustained.

If an active market

does not develop, holders of our common stock may be unable to readily sell the shares they hold or may not be able to sell their shares

at all, which may result in the loss of any investment in the Company or our securities.

common stock prices have been, and may continue to be, volatile and could decline substantially.

market price of our common stock may be highly volatile and subject to wide fluctuations.

Our financial performance, government regulatory

action, tax laws, interest rates, and market conditions in general could have a significant impact on the future market price of our

common stock.

of the factors that could negatively affect or result in fluctuations in the market price of our common stock include:

actual or anticipated

variations in our quarterly operating results;

changes in market valuations

of similar companies;

adverse market reaction

to the level of our indebtedness;

additions or departures

of key personnel;

If an active market does not develop,

holders of our common stock may be unable to readily sell the shares they hold or may not be able to sell their shares at all, which may

result in the loss of any investment in the Company or our securities.

Our common stock prices

have been, and may continue to be, volatile and could decline substantially.(*)

The market price of our common

stock may be highly volatile and subject to wide fluctuations.

Our financial performance, government regulatory action, tax laws, interest

rates, and market conditions in general could have a significant impact on the future market price of our common stock.

Some of the factors that could

negatively affect or result in fluctuations in the market price of our common stock include:

actual or anticipated variations in our quarterly operating results;

changes in market valuations of similar companies;

adverse market reaction to the level of our indebtedness;

additions or departures of key personnel;

actions by shareholders;

speculation in the press

or investment community;

general market, economic,

and political conditions, including an economic slowdown or dislocation in the global credit markets;

announcements by us or

our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments;

general economic and market

disputes or other developments

related to our intellectual property or other proprietary rights, including litigation;

our operating performance

and the performance of other similar companies;

speculation in the press or investment community;

general market, economic, and political conditions, including an economic slowdown or dislocation in the global credit markets;

announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments;

general economic and market conditions;

disputes or other developments related to our intellectual property or other proprietary rights, including litigation;

our operating performance and the performance of other similar companies;

changes in accounting principles;

passage of legislation

or other regulatory developments that adversely affect us or our industry.

is no guarantee that we will be able to comply with Nasdaq’s continued listing standards.

a condition to consummating our IPO, we were required to list our common stock on The Nasdaq Capital Market.

Notwithstanding the listing

of our common stock for trading on Nasdaq, there can be no assurance any broker will be interested in trading our securities.

it may be difficult to sell your shares of common stock if you desire or need to sell them.

Our underwriters are not obligated to make

a market in our securities, and even they do make a market, they can discontinue market making at any time without notice.

nor the underwriters can provide any assurance that an active and liquid trading market in our securities will develop or, if developed,

that such market will continue.

there is no guarantee that we will be able to maintain our listing on The Nasdaq Capital Market for any period of time.

Among the conditions

required for continued listing on The Nasdaq Capital Market, we must (i) maintain at least $2.5 million in shareholders’ equity;

$500,000 in net income over the prior two years or two of the prior three years;

or at least $35 million in market value of listed securities,

(ii) have a majority of independent directors (subject to certain “controlled company” exemptions, which we do not currently

plan to take advantage of, as discussed in greater detail above under “ Jacob D.

Cohen, our Chairman and Chief Executive Officer,

beneficially owns greater than 50% of our outstanding shares of common stock, which cause us to be deemed a “controlled company”

under the rules of Nasdaq.

passage of legislation or other regulatory developments that adversely affect us or our industry.

There is no guarantee that

we will be able to comply with Nasdaq’s continued listing standards.(*)

As a condition to consummating

our IPO, we were required to list our common stock on The Nasdaq Capital Market.

Notwithstanding the listing of our common stock for trading

on Nasdaq, there can be no assurance any broker will be interested in trading our securities.

Therefore, it may be difficult to sell your

shares of common stock if you desire or need to sell them.

Our underwriters are not obligated to make a market in our securities, and

even they do make a market, they can discontinue market making at any time without notice.

Neither we nor the underwriters can provide

any assurance that an active and liquid trading market in our securities will develop or, if developed, that such market will continue.

Furthermore, there is no guarantee that we will be able to maintain our

listing on The Nasdaq Capital Market for any period of time.

Among the conditions required for continued listing on The Nasdaq Capital

Market, we must (i) maintain at least $2.5 million in stockholders’ equity;

$500,000 in net income over the prior two years or two

of the prior three years;

or at least $35 million in market value of listed securities, (ii) have a majority of independent directors,

and (iii) maintain a stock bid price over $1.00 per share.

Our shareholders’ equity may

not remain above Nasdaq’s $2.5 million minimum, we may not generate over $500,000 of yearly net income moving forward, we may not

be able to maintain independent directors (to the extent required).

Recently our common stock price has traded below $1.00 per share

and we may not be able to maintain a stock price over $1.00 per share.

Our failure to meet the continued listing standards of Nasdaq

may result in our securities being delisted from The Nasdaq Capital Market.

absence of such a listing may adversely affect the acceptance of our common stock as currency or the value accorded by other parties.

Further, if we are delisted, we would also incur additional costs under state blue sky laws in connection with any sales of our securities.

These requirements could severely limit the market liquidity of our common stock and the ability of our shareholders to sell our common

stock in the secondary market.

If our common stock is delisted by Nasdaq, our common stock may be eligible to trade on an over-the-counter

quotation system, such as the OTCQB Market or OTC Pink Market, where an investor may find it more difficult to sell our securities or

obtain accurate quotations as to the market value of our securities.

In the event our common stock is delisted from Nasdaq in the future,

we may not be able to list our common stock or warrants on another national securities exchange or obtain quotation on an over-the counter

quotation system.

have broad discretion in how we use the proceeds of our IPO and may not use such proceeds effectively, which could affect our results

of operations and cause our common stock to decline.(*)

have considerable discretion in the application of the net proceeds of our IPO.

We have used, and plan to continue to use, the net proceeds

from the IPO for product development, marketing and advertising, and for working capital, and potentially for future acquisitions, although

none are currently planned.

We may use the net proceeds for purposes that do not yield a significant return or any return at all for

our shareholders.

In addition, pending their use, we may invest the net proceeds from the IPO in a manner that does not produce income

or that loses value.

our stock price fluctuates, you could lose a significant part of your investment.(*)

market price of our common stock could be subject to wide fluctuations in response to, among other things, the risk factors described

in this Report, and other factors beyond our control, such as fluctuations in the valuation of companies perceived by investors to be

comparable to us For example, since our common stock began trading on the Nasdaq Capital Market in connection with our IPO on March 20,

2023, the trading price of our common stock has traded as high as $4.37 and as low as $0.86 per share.

Furthermore, the stock markets

have experienced price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many

These fluctuations often have been unrelated or disproportionate to the operating performance of those companies.

market and industry fluctuations, as well as general economic, political, and market conditions, such as recessions, interest rate changes

or international currency fluctuations, may negatively affect the market price of our common stock.

In the past, many companies that

have experienced volatility in the market price of their stock have been subject to securities class action litigation.

We may be the

target of this type of litigation in the future.

Securities litigation against us could result in substantial costs and divert our management’s

attention from other business concerns, which could seriously harm our business.

securities or industry analysts do not publish research or reports about us, or if they adversely change their recommendations regarding

our common stock, then our stock price and trading volume could decline.

trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us,

our industry and our market.

If no analyst elects to cover us and publish research or reports about us, the market for our common stock

could be severely limited and our stock price could be adversely affected.

As a small-cap company, we are more likely than our larger

competitors to lack coverage from securities analysts.

In addition, even if we receive analyst coverage, if one or more analysts ceases

coverage of us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause

our stock price or trading volume to decline.

If one or more analysts who elect to cover us issue negative reports or adversely change

their recommendations regarding our common stock, our stock price could decline.

sales of our common stock, other securities convertible into our common stock, or preferred stock could cause the market value of our

common stock to decline and could result in dilution of your shares.(*)

Board of Directors is authorized, without your approval, to cause us to issue additional shares of our common stock or to raise

capital through the creation and issuance of preferred stock, other debt securities convertible into common stock, options, warrants

and other rights, on terms and for consideration as our Board of Directors in its sole discretion may determine.

Our stockholders’ equity may not remain above Nasdaq’s $2.5 million

minimum (our current stockholders’ equity is $3.0 million), we may not generate over $500,000 of yearly net income moving forward

(we have not generated net income to date), and we may not be able to maintain independent directors (to the extent required).

Additionally,

pursuant to the Resale Prospectus, registered the resale of an aggregate of 4,765,000 shares of common stock, which shares of common

stock are available for immediate resale in the public market (assuming the exercise of warrants to purchase 2,000,000 of such

shares, of which 1.55 million shares of common stock remain issuable thereunder).

An additional 87,500 shares of common stock are

issuable upon exercise of outstanding warrants to purchase shares at $5.00 per share, which were issued in connection with the IPO,

which are first exercisable on September 20, 2023.

Sales of substantial amounts of our common stock or of preferred stock could

cause the market price of our common stock to decrease significantly.

We cannot predict the effect, if any, of future sales of our

common stock, or the availability of our common stock for future sales, on the value of our common stock.

Sales of substantial

amounts of our common stock by large shareholders, or the perception that such sales could occur, may adversely affect the market

price of our common stock.

addition, in connection with our IPO, we, our directors, executive officers, and shareholders holding 5% or more of our outstanding common

stock have agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any

of our securities for a period of 12 months following the closing of the IPO (until March 20, 2024), subject to certain exceptions and

shareholders holding between 1% and 4.99% of our outstanding common stock have agreed not to offer, issue, sell, contract to sell, encumber,

grant any option for the sale of or otherwise dispose of any of our securities for a period of six months following the closing of the

IPO (until September 20, 2023), subject to certain exceptions.

Notwithstanding the above, now shares of common stock that are included

in the Resale Prospectus are subject to such lock-up agreements.

The representative of the IPO underwriters may, at any time, release,

or authorize us to release, as the case may be, all or a portion of our common stock subject to the foregoing lock-up provisions.

the restrictions under the lock-up provisions of the lock-up agreements entered into in connection with the IPO are waived, shares of

our common stock may become available for sale into the market, subject to applicable law, which could reduce the market price for our

recently our common stock price has traded below $1.00 per share and we may not be able to maintain a stock price over $1.00 per share.

Our failure to meet the continued listing standards of Nasdaq may result in our securities being delisted from The Nasdaq Capital Market.

The absence of such a listing

may adversely affect the acceptance of our common stock as currency or the value accorded by other parties.

Further, if we are delisted,

we would also incur additional costs under state blue sky laws in connection with any sales of our securities.

These requirements could

severely limit the market liquidity of our common stock and the ability of our shareholders to sell our common stock in the secondary

If our common stock is delisted by Nasdaq, our common stock may be eligible to trade on an over-the-counter quotation system,

such as the OTCQB Market or OTC Pink Market, where an investor may find it more difficult to sell our securities or obtain accurate quotations

as to the market value of our securities.

In the event our common stock is delisted from Nasdaq in the future, we may not be able to list

our common stock or warrants on another national securities exchange or obtain quotation on an over-the counter quotation system.

We have broad discretion

in how we use the proceeds of our IPO and may not use such proceeds effectively, which could affect our results of operations and cause

our common stock to decline.(*)

We have considerable discretion

in the application of the net proceeds of our IPO.

We have used, and plan to continue to use, the net proceeds from the IPO for product

development, marketing and advertising, and for working capital, and potentially for future acquisitions, although none are currently

We may use the net proceeds for purposes that do not yield a significant return or any return at all for our shareholders.

addition, pending their use, we may invest the net proceeds from the IPO in a manner that does not produce income or that loses value.

If our stock price fluctuates,

you could lose a significant part of your investment.(*)

The market price of our common

stock could be subject to wide fluctuations in response to, among other things, the risk factors described in this Report, and other factors

beyond our control, such as fluctuations in the valuation of companies perceived by investors to be comparable to us For example, since

our common stock began trading on the Nasdaq Capital Market in connection with our IPO on March 20, 2023, the trading price of our common

stock has traded as high as $4.37 and as low as $0.86 per share.

Furthermore, the stock markets have experienced price and volume fluctuations

that have affected and continue to affect the market prices of equity securities of many companies.

These fluctuations often have been

unrelated or disproportionate to the operating performance of those companies.

These broad market and industry fluctuations, as well as

general economic, political, and market conditions, such as recessions, interest rate changes or international currency fluctuations,

may negatively affect the market price of our common stock.

In the past, many companies that have experienced volatility in the market

price of their stock have been subject to securities class action litigation.

We may be the target of this type of litigation in the future.

Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns,

which could seriously harm our business.

If securities or industry

analysts do not publish research or reports about us, or if they adversely change their recommendations regarding our common stock, then

our stock price and trading volume could decline.

The trading market for our common

stock is influenced by the research and reports that industry or securities analysts publish about us, our industry and our market.

no analyst elects to cover us and publish research or reports about us, the market for our common stock could be severely limited and

our stock price could be adversely affected.

As a small-cap company, we are more likely than our larger competitors to lack coverage from

securities analysts.

In addition, even if we receive analyst coverage, if one or more analysts ceases coverage of us or fails to regularly

publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume

If one or more analysts who elect to cover us issue negative reports or adversely change their recommendations regarding our

common stock, our stock price could decline.

Future sales of our common

stock, other securities convertible into our common stock, or preferred stock could cause the market value of our common stock to decline

and could result in dilution of your shares.(*)

Our Board of Directors is

authorized, without your approval, to cause us to issue additional shares of our common stock or to raise capital through the

creation and issuance of preferred stock, other debt securities convertible into common stock, options, warrants and other rights,

on terms and for consideration as our Board of Directors in its sole discretion may determine.

Additionally, pursuant to the Resale

Prospectus, registered the resale of an aggregate of 4,765,000 shares of common stock, which shares of common stock are available

for immediate resale in the public market (which number includes 2,000,000 shares of common stock issuable upon the exercise of

warrants, of which 975,500 shares of common stock remain issuable thereunder as of the date of this Report).

An additional

87,500 shares of common stock are issuable upon exercise of outstanding warrants to purchase shares at $5.00 per share, which were

issued in connection with the IPO, which are first exercisable on September 20, 2023.

Sales of substantial amounts of our common

stock or of preferred stock could cause the market price of our common stock to decrease significantly.

We cannot predict the

effect, if any, of future sales of our common stock, or the availability of our common stock for future sales, on the value of our

common stock.

have no intention of declaring dividends in the foreseeable future.

decision to pay cash dividends on our common stock rests with our Board of Directors and will depend on our earnings, unencumbered cash,

capital requirements and financial condition.

We do not anticipate declaring any dividends in the foreseeable future, as we intend to

use any excess cash to fund our operations.

Investors in our common stock should not expect to receive dividend income on their investment,

and investors will be dependent on the appreciation of our common stock to earn a return on their investment.

issuance and sale of common stock upon exercise of outstanding warrants may cause substantial dilution to existing shareholders and may

also depress the market price of our common stock.

Outstanding warrants to purchase shares of our common stock have cashless exercise

of the date of this Report, we had a total of 1,637,500 warrants outstanding with a weighted average exercise price of $1.17 per share

and term ranging from August 16, 2027 through March 20, 2028.

If the holders of the warrants choose to exercise the warrants, it

will cause substantial dilution to the then holders of our common stock.

If exercises of the warrants and sales of such shares

issuable upon exercise thereof take place, the price of our common stock may decline.

In addition, the common stock issuable upon

exercise of the warrants may represent overhang that may also adversely affect the market price of our common stock.

Overhang occurs

when there is a greater supply of a company’s stock in the market than there is demand for that stock.

When this happens the

price of our stock will decrease, and any additional shares which shareholders attempt to sell in the market will only further

decrease the share price.

If the share volume of our common stock cannot absorb shares sold by the warrant holders, then the value

of our common stock will likely decrease.

of the warrants discussed above allow for cashless exercise rights.

In a ‘cashless exercise’, the holder reduces the number

of shares of common stock issuable upon exercise of the warrants in amount equal to the aggregate value of the exercise price of the

exercised warrants.

For example, if our common stock was trading at $2.00 per share and a holder desires to exercise warrants to purchase

100 shares of common stock with an exercise price of $1.00 per share on a cashless basis, the number of shares of common stock issuable

to the holder upon such exercise would be reduced by 50 shares, equal in value to $100 ($2.00 per share x 50 shares), and the holder

would receive 50 shares of common stock upon such exercise.

We do not receive any cash upon a cashless exercise and as such, while a

cashless exercise reduces the dilution which would otherwise exist upon a warrant exercise, it is also not as beneficial to us, as it

does not bring in any new investment proceeds.

Additionally, holders of warrants with cashless exercise provisions may be more likely

to exercise their warrants as they do not have to come out of pocket with any cash exercise payments.

industry and the broader U.S.

economy experienced higher than expected inflationary pressures during 2022 related to continued supply

chain disruptions, labor shortages and geopolitical instability, and if these conditions persist, our business, results of operations

and cash flows could be materially and adversely affected.

saw significant increases in the costs of labor and certain materials and equipment, and longer lead times for such materials and equipment,

as a result of availability constraints, supply chain disruption, increased demand, labor shortages associated with a fully employed

labor force, high inflation and other factors.

Supply and demand fundamentals have been further aggravated by disruptions in global

energy supply caused by multiple geopolitical events, including the ongoing conflict between Russia and Ukraine.

Recent supply chain

constraints and inflationary pressures may in the future adversely impact our operating costs, and as a result, our business, financial

condition, results of operations and cash flows could be materially and adversely affected.

and the health and wellness industry in general may be adversely affected during periods of high inflation, primarily because of higher

shipping and product manufacturing costs.

While we plan to attempt to pass on increases in our costs through increased sales prices,

market forces may limit our ability to do so.

If we are unable to raise sales prices enough to compensate for higher costs, our future

revenues, gross profit margin and revenues could be adversely affected.

uncertainty may affect our access to capital and/or increase the costs of such capital.

economic conditions continue to be volatile and uncertain due to, among other things, consumer confidence in future economic conditions,

fears of recession and trade wars, the price of energy, fluctuating interest rates, the availability and cost of consumer credit, the

availability and timing of government stimulus programs, levels of unemployment, increased inflation, tax rates, and the war between

Ukraine and Russia which began in February 2022.

These conditions remain unpredictable and create uncertainties about our ability to

raise capital in the future.

In the event required capital becomes unavailable in the future, or more costly, it could have a material

adverse effect on our business, future results of operations, and financial condition.

business may be materially and adversely disrupted by epidemics or pandemics in the future, including COVID-19.(*)

epidemic, pandemic or similar serious public health issue, and the measures undertaken by governmental authorities to address it, could

significantly disrupt or prevent us from operating our business in the ordinary course for an extended period, and thereby, and/or along

with any associated economic and/or social instability or distress, have a material adverse impact on our financial statements.

March 11, 2020, the World Health Organization characterized the outbreak of COVID-19 as a global pandemic and recommended containment

and mitigation measures.

On March 13, 2020, the United States declared a national emergency concerning the outbreak, and several states

and municipalities have declared public health emergencies.

Sales of substantial amounts of our common stock by large shareholders, or the perception that such sales could occur,

may adversely affect the market price of our common stock.

In addition, in connection

with our IPO, we, our directors, executive officers, and shareholders holding 5% or more of our outstanding common stock have agreed

not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our

securities for a period of 12 months following the closing of the IPO (until March 20, 2024), subject to certain exceptions and

shareholders holding between 1% and 4.99% of our outstanding common stock have agreed not to offer, issue, sell, contract to sell,

encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of six months following the

closing of the IPO (until September 20, 2023), subject to certain exceptions.

Notwithstanding the above, no shares of common stock

that are included in the Resale Prospectus are subject to such lock-up agreements.

The representative of the IPO underwriters may,

at any time, release, or authorize us to release, as the case may be, all or a portion of our common stock subject to the foregoing

lock-up provisions without required notice.

If the restrictions under the lock-up provisions of the lock-up agreements entered into in connection with the

IPO are waived, shares of our common stock may become available for sale into the market, subject to applicable law, which could

reduce the market price for our common stock.

We have no intention of

declaring dividends in the foreseeable future.

The decision to pay cash dividends

on our common stock rests with our Board of Directors and will depend on our earnings, unencumbered cash, capital requirements and financial

We do not anticipate declaring any dividends in the foreseeable future, as we intend to use any excess cash to fund our operations.

Investors in our common stock should not expect to receive dividend income on their investment, and investors will be dependent on the

appreciation of our common stock to earn a return on their investment.

The issuance and sale of

common stock upon exercise of outstanding warrants may cause substantial dilution to existing shareholders and may also depress the market

price of our common stock.

Outstanding warrants to purchase shares of our common stock have cashless exercise rights.(*)

As of the date of this Report,

we had a total of 1,063,000 warrants outstanding with a weighted average exercise price of $1.17 per share and term ranging from August

16, 2027 through March 20, 2028.

If the holders of the warrants choose to exercise the warrants, it may cause significant dilution to

the then holders of our common stock.

If exercises of the warrants and sales of such shares issuable upon exercise thereof take place,

the price of our common stock may decline.

In addition, the common stock issuable upon exercise of the warrants may represent overhang

that may also adversely affect the market price of our common stock.

Overhang occurs when there is a greater supply of a company’s

stock in the market than there is demand for that stock.

When this happens the price of our stock will decrease, and any additional shares

which shareholders attempt to sell in the market will only further decrease the share price.

If the share volume of our common stock cannot

absorb shares sold by the warrant holders, then the value of our common stock will likely decrease.

A total of 87,500 of the

warrants discussed above (which have an exercise price of $5.00 per share) currently allow for cashless exercise rights.

‘cashless exercise’, the holder reduces the number of shares of common stock issuable upon exercise of the warrants in

amount equal to the aggregate value of the exercise price of the exercised warrants.

For example, if our common stock was trading at

$2.00 per share and a holder desires to exercise warrants to purchase 100 shares of common stock with an exercise price of $1.00 per

share on a cashless basis, the number of shares of common stock issuable to the holder upon such exercise would be reduced by 50

shares, equal in value to $100 ($2.00 per share x 50 shares), and the holder would receive 50 shares of common stock upon such

We do not receive any cash upon a cashless exercise and as such, while a cashless exercise reduces the dilution which

would otherwise exist upon a warrant exercise, it is also not as beneficial to us, as it does not bring in any new investment

Additionally, holders of warrants with cashless exercise provisions may be more likely to exercise their warrants as they

do not have to come out of pocket with any cash exercise payments.

General Risk Factors

Our industry and the broader

economy experienced higher than expected inflationary pressures during 2022 related to continued supply chain disruptions, labor

shortages and geopolitical instability, and if these conditions persist, our business, results of operations and cash flows could be materially

and adversely affected.

2022 saw significant increases

in the costs of labor and certain materials and equipment, and longer lead times for such materials and equipment, as a result of availability

constraints, supply chain disruption, increased demand, labor shortages associated with a fully employed U.S.

labor force, high inflation

and other factors.

Supply and demand fundamentals have been further aggravated by disruptions in global energy supply caused by multiple

geopolitical events, including the ongoing conflict between Russia and Ukraine.

Recent supply chain constraints and inflationary pressures

may in the future adversely impact our operating costs, and as a result, our business, financial condition, results of operations and

cash flows could be materially and adversely affected.

We and the health and wellness

industry in general may be adversely affected during periods of high inflation, primarily because of higher shipping and product manufacturing

While we plan to attempt to pass on increases in our costs through increased sales prices, market forces may limit our ability

If we are unable to raise sales prices enough to compensate for higher costs, our future revenues, gross profit margin and revenues

could be adversely affected.

Economic uncertainty may

affect our access to capital and/or increase the costs of such capital.(*)

Global economic conditions continue

to be volatile and uncertain due to, among other things, consumer confidence in future economic conditions, fears of recession and trade

wars, the price of energy, fluctuating interest rates, the availability and cost of consumer credit, the availability and timing of government

stimulus programs, levels of unemployment, increased inflation, tax rates, and the war between Ukraine and Russia which began in February

2022, and has continued through the date of this Report.

These conditions remain unpredictable and create uncertainties about our ability to raise capital in the future.

In the event required

capital becomes unavailable in the future, or more costly, it could have a material adverse effect on our business, future results of

operations, and financial condition.

Our business may be materially

and adversely disrupted by epidemics or pandemics in the future, including COVID-19.(*)

An epidemic, pandemic or similar

serious public health issue, and the measures undertaken by governmental authorities to address it, could significantly disrupt or prevent

us from operating our business in the ordinary course for an extended period, and thereby, and/or along with any associated economic and/or

social instability or distress, have a material adverse impact on our financial statements.

On March 11, 2020, the World Health

Organization characterized the outbreak of COVID-19 as a global pandemic and recommended containment and mitigation measures.

13, 2020, the United States declared a national emergency concerning the outbreak, and several states and municipalities have declared

public health emergencies.

Congress formally ended the COVID-19 national emergency on April 10, 2023.

Although COVID-19 has to date not had a material impact on our operations, should the COVID-19 public health effort re-intensify

to such an extent that we cannot operate, if there are new government restrictions on our business and our customers, and/or an extended

economic recession or significant inflation, we could be unable to produce significant revenues and cash flows sufficient to conduct

our business.

Such a circumstance could, among other things, exhaust our available liquidity (and ability to access liquidity sources)

and/or trigger an acceleration to pay a significant portion or all of our then-outstanding debt obligations, which we may be unable to

business could be disrupted by catastrophic events and man-made problems, such as power disruptions, data security breaches, and terrorism.

systems will be vulnerable to damage or interruption from the occurrence of any catastrophic event, including earthquake, fire, flood,

or other weather event, power loss, telecommunications failure, software or hardware malfunction, cyber-attack, war, terrorist attack,

or incident of mass violence, which could result in lengthy interruptions in access to our systems.

In addition, acts of terrorism, including

malicious internet-based activity, could cause disruptions to the internet or the economy as a whole.

If our systems were to fail or

be negatively impacted as a result of a natural disaster or other event, our ability to provide products to customers would be impaired

or we could lose critical data.

We do not carry business interruption insurance sufficient to compensate us for the potentially significant

losses, including the potential harm to our business, financial condition and results of operations that may result from interruptions

in access to our platform as a result of system failures.

operations are subject to risks associated with ongoing and potential future global conflicts.

there is an ongoing conflict involving Russia and Ukraine and the war between the two countries continues to evolve as military activity

proceeds and additional sanctions are imposed.

The war is increasingly affecting economic and global financial markets and exacerbating

ongoing economic challenges, including issues such as rising inflation and global supply-chain disruption.

While we do not believe this

conflict currently has a material impact on our financial accounting and reporting, the degree to which we will be affected in the future

largely depends on the nature and duration of uncertain and unpredictable events, and our business could be impacted.

Furthermore, future

global conflicts or wars could create further economic challenges, including, but not limited to, increases in inflation and further

global supply-chain disruption.

Consequently, the ongoing Russia/Ukraine conflict and/or other future global conflicts could result in

an increase in operating expenses and/or a decrease in any future revenue and could further have a material adverse effect on our results

of operations and cash flow.

economic conditions could materially adversely affect our business, results of operations, financial condition and growth.

macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs, changes to fiscal and monetary policy,

tighter credit, higher interest rates, high unemployment and currency fluctuations could materially adversely affect our operations,

expenses, access to capital and the market for our products.

In addition, consumer confidence and spending could be adversely affected

in response to financial market volatility, negative financial news, conditions in the real estate and mortgage markets, declines in

income or asset values, changes to fuel and other energy costs, labor and healthcare costs and other economic factors.

addition, uncertainty about, or a decline in, global or regional economic conditions could have a significant impact on our expected

funding sources, suppliers and partners.

Although COVID-19 has to

date not had a material impact on our operations, should the COVID-19 public health effort re-intensify to such an extent that we cannot

operate, if there are new government restrictions on our business and our customers, and/or an extended economic recession or significant

inflation, we could be unable to produce significant revenues and cash flows sufficient to conduct our business.

Such a circumstance could,

among other things, exhaust our available liquidity (and ability to access liquidity sources) and/or trigger an acceleration to pay a

significant portion or all of our then-outstanding debt obligations, which we may be unable to do.

Our business could be disrupted

by catastrophic events and man-made problems, such as power disruptions, data security breaches, and terrorism.

Our systems will be vulnerable

to damage or interruption from the occurrence of any catastrophic event, including earthquake, fire, flood, or other weather event, power

loss, telecommunications failure, software or hardware malfunction, cyber-attack, war, terrorist attack, or incident of mass violence,

which could result in lengthy interruptions in access to our systems.

In addition, acts of terrorism, including malicious internet-based

activity, could cause disruptions to the internet or the economy as a whole.

If our systems were to fail or be negatively impacted as

a result of a natural disaster or other event, our ability to provide products to customers would be impaired or we could lose critical

We do not carry business interruption insurance sufficient to compensate us for the potentially significant losses, including the

potential harm to our business, financial condition and results of operations that may result from interruptions in access to our platform

as a result of system failures.

Our operations are subject

to risks associated with ongoing and potential future global conflicts.

Currently, there is an ongoing

conflict involving Russia and Ukraine and the war between the two countries continues to evolve as military activity proceeds and additional

sanctions are imposed.

The war is increasingly affecting economic and global financial markets and exacerbating ongoing economic challenges,

including issues such as rising inflation and global supply-chain disruption.

While we do not believe this conflict currently has a material

impact on our financial accounting and reporting, the degree to which we will be affected in the future largely depends on the nature

and duration of uncertain and unpredictable events, and our business could be impacted.

Furthermore, future global conflicts or wars could

create further economic challenges, including, but not limited to, increases in inflation and further global supply-chain disruption.

Consequently, the ongoing Russia/Ukraine conflict and/or other future global conflicts could result in an increase in operating expenses

and/or a decrease in any future revenue and could further have a material adverse effect on our results of operations and cash flow.

Global economic conditions

could materially adversely affect our business, results of operations, financial condition and growth.

Adverse macroeconomic conditions,

including inflation, slower growth or recession, new or increased tariffs, changes to fiscal and monetary policy, tighter credit, higher

interest rates, high unemployment and currency fluctuations could materially adversely affect our operations, expenses, access to capital

and the market for our products.

In addition, consumer confidence and spending could be adversely affected in response to financial market

volatility, negative financial news, conditions in the real estate and mortgage markets, declines in income or asset values, changes to

fuel and other energy costs, labor and healthcare costs and other economic factors.

In addition, uncertainty about,

or a decline in, global or regional economic conditions could have a significant impact on our expected funding sources, suppliers and

Potential effects include financial instability;

inability to obtain credit to finance operations

and purchases of our products;

inability to obtain credit to finance operations and purchases of our products;

and insolvency.

downturn in the economic environment could also lead to limitations on our ability to issue new debt;

A downturn in the economic environment

could also lead to limitations on our ability to issue new debt;

reduced liquidity;

in the fair value of our financial instruments.

These and other economic factors could materially adversely affect our business, results

of operations, financial condition and growth.

may become party to litigation, mediation and/or arbitration from time to time given our product focus.

may become party to regulatory proceedings, litigation, mediation and/or arbitration from time to time in the ordinary course of business

which could adversely affect our business.

Monitoring and defending against legal actions, whether or not meritorious, can be time-consuming,

divert management’s attention and resources and cause us to incur significant expenses.

In addition, legal fees and costs incurred

in connection with such activities may be significant and we could, in the future, be subject to judgments or enter into settlements

of claims for significant monetary damages.

While we expect to have insurance in the future that may cover the costs and awards of certain

types of litigation, the amount of our future insurance may not be sufficient to cover any costs or awards.

Substantial litigation costs

or an adverse result in any litigation may adversely impact our business, operating results or financial condition.

labor costs due to statutory and regulatory changes could materially adversely affect our business, financial condition and operating

federal and state labor laws, including new laws and regulations enacted in response to COVID-19, govern our relationships with our employees

and affect operating costs.

These laws include employee classifications as exempt or non-exempt, minimum wage requirements, unemployment

tax rates, workers’ compensation rates, overtime, family leave, workplace health and safety standards, payroll taxes, citizenship

requirements and other wage and benefit requirements for employees classified as non-exempt.

As certain of our employees are paid at

rates set at, or above but related to, the applicable minimum wage, further increases in the minimum wage could increase our labor costs.

Significant additional government regulations could materially adversely affect our business, financial condition and operating results.

to adequately manage our planned aggressive growth strategy may harm our business or increase our risk of failure.

the foreseeable future, we intend to pursue an aggressive growth strategy for the expansion of our operations through increased marketing.

Our ability to rapidly expand our operations will depend upon many factors, including our ability to work in a regulated environment,

establish and maintain strategic relationships with suppliers, and obtain adequate capital resources on acceptable terms.

Any restrictions

on our ability to expand may have a materially adverse effect on our business, results of operations, and financial condition.

we may be unable to achieve our targets for sales growth, and our operations may not be successful or achieve anticipated operating results.

Additionally,

our growth may place a significant strain on our managerial, administrative, operational, and financial resources and our infrastructure.

Our future success will depend, in part, upon the ability of our senior management to manage growth effectively.

This will require us

to, among other things:

implement additional

management information systems;

further develop our operating,

administrative, legal, financial, and accounting systems and controls;

and declines in the fair value of our financial instruments.

These and other economic factors could materially adversely affect our business, results of operations, financial condition and growth.

We may become party to litigation,

mediation and/or arbitration from time to time given our product focus.

We may become party to regulatory

proceedings, litigation, mediation and/or arbitration from time to time in the ordinary course of business which could adversely affect

our business.

Monitoring and defending against legal actions, whether or not meritorious, can be time-consuming, divert management’s

attention and resources and cause us to incur significant expenses.

In addition, legal fees and costs incurred in connection with such

activities may be significant and we could, in the future, be subject to judgments or enter into settlements of claims for significant

monetary damages.

While we expect to have insurance in the future that may cover the costs and awards of certain types of litigation,

the amount of our future insurance may not be sufficient to cover any costs or awards.

Substantial litigation costs or an adverse result

in any litigation may adversely impact our business, operating results or financial condition.

Higher labor costs due to

statutory and regulatory changes could materially adversely affect our business, financial condition and operating results.

Various federal and state labor

laws, including new laws and regulations enacted in response to COVID-19, govern our relationships with our employees and affect operating

These laws include employee classifications as exempt or non-exempt, minimum wage requirements, unemployment tax rates, workers’

compensation rates, overtime, family leave, workplace health and safety standards, payroll taxes, citizenship requirements and other wage

and benefit requirements for employees classified as non-exempt.

As certain of our employees are paid at rates set at, or above but related

to, the applicable minimum wage, further increases in the minimum wage could increase our labor costs.

Significant additional government

regulations could materially adversely affect our business, financial condition and operating results.

Failure to adequately manage

our planned aggressive growth strategy may harm our business or increase our risk of failure.

For the foreseeable future, we

intend to pursue an aggressive growth strategy for the expansion of our operations through increased marketing.

Our ability to rapidly

expand our operations will depend upon many factors, including our ability to work in a regulated environment, establish and maintain

strategic relationships with suppliers, and obtain adequate capital resources on acceptable terms.

Any restrictions on our ability to

expand may have a materially adverse effect on our business, results of operations, and financial condition.

Accordingly, we may be unable

to achieve our targets for sales growth, and our operations may not be successful or achieve anticipated operating results.

Additionally, our growth

may place a significant strain on our managerial, administrative, operational, and financial resources and our infrastructure.

success will depend, in part, upon the ability of our senior management to manage growth effectively.

This will require us to, among other

implement additional management information systems;

further develop our operating, administrative, legal, financial, and accounting systems and controls;

hire additional personnel;

develop additional levels

of management within our company;

locate additional office

maintain close coordination

among our operations, legal, finance, sales and marketing, and client service and support personnel.

a result, we may lack the resources to deploy our services on a timely and cost-effective basis.

Failure to accomplish any of these requirements

could impair our ability to deliver services in a timely fashion or attract and retain new customers.

we make any acquisitions, they may disrupt or have a negative impact on our business.

we make acquisitions in the future, we could have difficulty integrating the acquired company’s assets, personnel and operations

with our own.

We do not anticipate that any acquisitions or mergers we may enter into in the future would result in a change of control

of the Company.

In addition, the key personnel of the acquired business may not be willing to work for us.

We cannot predict the effect

expansion may have on our core business.

Regardless of whether we are successful in making an acquisition, the negotiations could disrupt

our ongoing business, distract our management and employees and increase our expenses.

In addition to the risks described above, acquisitions

are accompanied by a number of inherent risks, including, without limitation, the following:

the difficulty

of integrating acquired products, services or operations;

the potential disruption

of the ongoing businesses and distraction of our management and the management of acquired companies;

difficulties in maintaining

uniform standards, controls, procedures and policies;

the potential

impairment of relationships with employees and customers as a result of any integration of new management personnel;

the potential inability

or failure to achieve additional sales and enhance our customer base through cross-marketing of the products to new and existing

of any government regulations which relate to the business acquired;

potential unknown liabilities

associated with acquired businesses or product lines, or the need to spend significant amounts to retool, reposition or modify the

marketing and sales of acquired products or operations, or the defense of any litigation, whether or not successful, resulting from

actions of the acquired company prior to our acquisition;

potential expenses under

the labor, environmental and other laws of various jurisdictions.

business could be severely impaired if and to the extent that we are unable to succeed in addressing any of these risks or other problems

encountered in connection with an acquisition, many of which cannot be presently identified.

These risks and problems could disrupt our

ongoing business, distract our management and employees, increase our expenses and adversely affect our results of operations.

litigation, government investigations, and other proceedings may adversely affect our business and results of operations.

may be subject to actual and threatened claims, litigation, reviews, investigations, and other proceedings, including proceedings relating

to products offered by us and by third parties, and other matters.

Any of these types of proceedings, may have an adverse effect on us

because of legal costs, disruption of our operations, diversion of management resources, negative publicity, and other factors.

of these matters are inherently unpredictable and subject to significant uncertainties.

Determining legal reserves and possible losses

from such matters involves judgment and may not reflect the full range of uncertainties and unpredictable outcomes.

Until the final resolution

of such matters, we may be exposed to losses in excess of the amount recorded, and such amounts could be material.

Should any of our

estimates and assumptions change or prove to have been incorrect, it could have a material effect on our business, financial

position, results of operations, or cash flows.

In addition, it is possible that a resolution of one or more such proceedings, including

as a result of a settlement, could require us to make substantial future payments, prevent us from offering certain products or services,

require us to change our business practices in a manner materially adverse to our business, requiring development of non-infringing or

otherwise altered products or technologies, damaging our reputation, or otherwise having a material effect on our operations.

may incur indebtedness in the future which could reduce our financial flexibility, increase interest expense and adversely impact our

operations and our costs.

may incur significant amounts of indebtedness in the future.

Our level of indebtedness could affect our operations in several ways, including

the following:

a significant

portion of our cash flows is required to be used to service our indebtedness;

a high level of debt increases

our vulnerability to general adverse economic and industry conditions;

covenants contained in

the agreements governing our outstanding indebtedness limit our ability to borrow additional funds and provide additional security

interests, dispose of assets, pay dividends and make certain investments;

a high level of debt may

place us at a competitive disadvantage compared to our competitors that are less leveraged and, therefore, may be able to take advantage

of opportunities that our indebtedness may prevent us from pursuing;

debt covenants may affect

our flexibility in planning for, and reacting to, changes in the economy and in our industry.

high level of indebtedness increases the risk that we may default on our debt obligations.

We may not be able to generate sufficient

cash flows to pay the principal or interest on our debt, and future working capital, borrowings or equity financing may not be available

to pay or refinance such debt.

If we do not have sufficient funds and are otherwise unable to arrange financing, we may have to sell

significant assets or have a portion of our assets foreclosed upon which could have a material adverse effect on our business, financial

condition and results of operations.

develop additional levels of management within our company;

locate additional office space;

maintain close coordination among our operations, legal, finance, sales and marketing, and client service and support personnel.

As a result, we may lack the resources

to deploy our services on a timely and cost-effective basis.

Failure to accomplish any of these requirements could impair our ability

to deliver services in a timely fashion or attract and retain new customers.

If we make any acquisitions,

they may disrupt or have a negative impact on our business.

If we make acquisitions in the

future, we could have difficulty integrating the acquired company’s assets, personnel and operations with our own.

We do not anticipate

that any acquisitions or mergers we may enter into in the future would result in a change of control of the Company.

In addition, the

key personnel of the acquired business may not be willing to work for us.

We cannot predict the effect expansion may have on our core

Regardless of whether we are successful in making an acquisition, the negotiations could disrupt our ongoing business, distract

our management and employees and increase our expenses.

In addition to the risks described above, acquisitions are accompanied by a number

of inherent risks, including, without limitation, the following:

the difficulty of integrating acquired products, services or operations;

the potential disruption of the ongoing businesses and distraction of our management and the management of acquired companies;

difficulties in maintaining uniform standards, controls, procedures and policies;

the potential impairment of relationships with employees and customers as a result of any integration of new management personnel;

the potential inability or failure to achieve additional sales and enhance our customer base through cross-marketing of the products to new and existing customers;

the effect of any government regulations which relate to the business acquired;

potential unknown liabilities associated with acquired businesses or product lines, or the need to spend significant amounts to retool, reposition or modify the marketing and sales of acquired products or operations, or the defense of any litigation, whether or not successful, resulting from actions of the acquired company prior to our acquisition;

potential expenses under the labor, environmental and other laws of various jurisdictions.

Our business could be severely

impaired if and to the extent that we are unable to succeed in addressing any of these risks or other problems encountered in connection

with an acquisition, many of which cannot be presently identified.

These risks and problems could disrupt our ongoing business, distract

our management and employees, increase our expenses and adversely affect our results of operations.

Claims, litigation, government

investigations, and other proceedings may adversely affect our business and results of operations.

We may be subject to actual and

threatened claims, litigation, reviews, investigations, and other proceedings, including proceedings relating to products offered by us

and by third parties, and other matters.

Any of these types of proceedings, may have an adverse effect on us because of legal costs, disruption

of our operations, diversion of management resources, negative publicity, and other factors.

The outcomes of these matters are inherently

unpredictable and subject to significant uncertainties.

Determining legal reserves and possible losses from such matters involves judgment

and may not reflect the full range of uncertainties and unpredictable outcomes.

Until the final resolution of such matters, we may be

exposed to losses in excess of the amount recorded, and such amounts could be material.

Should any of our estimates and assumptions change

or prove to have been incorrect, it could have a material effect on our business, financial position, results of operations, or cash flows.

In addition, it is possible that a resolution of one or more such proceedings, including as a result of a settlement, could require us

to make substantial future payments, prevent us from offering certain products or services, require us to change our business practices

in a manner materially adverse to our business, requiring development of non-infringing or otherwise altered products or technologies,

damaging our reputation, or otherwise having a material effect on our operations.

We may incur indebtedness

in the future which could reduce our financial flexibility, increase interest expense and adversely impact our operations and our costs.

We may incur significant amounts

of indebtedness in the future.

Our level of indebtedness could affect our operations in several ways, including the following:

a significant portion of our cash flows is required to be used to service our indebtedness;

a high level of debt increases our vulnerability to general adverse economic and industry conditions;

covenants contained in the agreements governing our outstanding indebtedness limit our ability to borrow additional funds and provide additional security interests, dispose of assets, pay dividends and make certain investments;

a high level of debt may place us at a competitive disadvantage compared to our competitors that are less leveraged and, therefore, may be able to take advantage of opportunities that our indebtedness may prevent us from pursuing;

debt covenants may affect our flexibility in planning for, and reacting to, changes in the economy and in our industry.

A high level of indebtedness increases

the risk that we may default on our debt obligations.

We may not be able to generate sufficient cash flows to pay the principal or interest

on our debt, and future working capital, borrowings or equity financing may not be available to pay or refinance such debt.

have sufficient funds and are otherwise unable to arrange financing, we may have to sell significant assets or have a portion of our assets

foreclosed upon which could have a material adverse effect on our business, financial condition and results of operations.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1A. Risk Factors